<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Pediatr</journal-id><journal-id journal-id-type="iso-abbrev">Front Pediatr</journal-id><journal-id journal-id-type="publisher-id">Front. Pediatr.</journal-id><journal-title-group><journal-title>Frontiers in Pediatrics</journal-title></journal-title-group><issn pub-type="epub">2296-2360</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27066464</article-id><article-id pub-id-type="pmc">4815896</article-id><article-id pub-id-type="doi">10.3389/fped.2016.00031</article-id><article-categories><subj-group subj-group-type="heading"><subject>Pediatrics</subject><subj-group><subject>Clinical Trial</subject></subj-group></subj-group></article-categories><title-group><article-title>Plasma Biomarker Analysis in Pediatric ARDS: Generating Future Framework from a Pilot Randomized Control Trial of Methylprednisolone: <italic>A Framework for Identifying Plasma Biomarkers Related to Clinical Outcomes in Pediatric ARDS</italic></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kimura</surname><given-names>Dai</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="corresp" rid="cor1">*</xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/285760"></uri></contrib><contrib contrib-type="author"><name><surname>Saravia</surname><given-names>Jordy</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/262579"></uri></contrib><contrib contrib-type="author"><name><surname>Rovnaghi</surname><given-names>Cynthia R.</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/306711"></uri></contrib><contrib contrib-type="author"><name><surname>Meduri</surname><given-names>Gianfranco Umberto</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref><xref ref-type="aff" rid="aff6"><sup>6</sup></xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/264624"></uri></contrib><contrib contrib-type="author"><name><surname>Schwingshackl</surname><given-names>Andreas</given-names></name><xref ref-type="aff" rid="aff7"><sup>7</sup></xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/69647"></uri></contrib><contrib contrib-type="author"><name><surname>Cormier</surname><given-names>Stephania A.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff8"><sup>8</sup></xref><xref ref-type="aff" rid="aff9"><sup>9</sup></xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/56545"></uri></contrib><contrib contrib-type="author"><name><surname>Anand</surname><given-names>Kanwaljeet J.</given-names></name><xref ref-type="aff" rid="aff10"><sup>10</sup></xref><xref ref-type="aff" rid="aff11"><sup>11</sup></xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/99925"></uri></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Department of Pediatrics, University of Tennessee Health Science Center</institution>, <addr-line>Memphis, TN</addr-line>, <country>USA</country></aff><aff id="aff2"><sup>2</sup><institution>Department of Pediatrics, Le Bonheur Children’s Hospital</institution>, <addr-line>Memphis, TN</addr-line>, <country>USA</country></aff><aff id="aff3"><sup>3</sup><institution>Children’s Foundation Research Institute at Le Bonheur Children’s Hospital</institution>, <addr-line>Memphis, TN</addr-line>, <country>USA</country></aff><aff id="aff4"><sup>4</sup><institution>Pain Neurobiology Laboratory, Stanford University</institution>, <addr-line>Palo Alto, CA</addr-line>, <country>USA</country></aff><aff id="aff5"><sup>5</sup><institution>Department of Internal Medicine, Memphis Veterans Affairs Medical Center</institution>, <addr-line>Memphis, TN</addr-line>, <country>USA</country></aff><aff id="aff6"><sup>6</sup><institution>Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, University of Tennessee Health Science Center</institution>, <addr-line>Memphis, TN</addr-line>, <country>USA</country></aff><aff id="aff7"><sup>7</sup><institution>Department of Pediatrics, University of California Los Angeles</institution>, <addr-line>Los Angeles, CA</addr-line>, <country>USA</country></aff><aff id="aff8"><sup>8</sup><institution>Department of Microbiology, Immunology and Biochemistry, University of Tennessee Health Science Center</institution>, <addr-line>Memphis, TN</addr-line>, <country>USA</country></aff><aff id="aff9"><sup>9</sup><institution>Department of Physiology, University of Tennessee Health Science Center</institution>, <addr-line>Memphis</addr-line>, <country>TN</country>, <country>USA</country></aff><aff id="aff10"><sup>10</sup><institution>Department of Pediatrics, Stanford University School of Medicine</institution>, <addr-line>Palo Alto, CA</addr-line>, <country>USA</country></aff><aff id="aff11"><sup>11</sup><institution>Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University School of Medicine</institution>, <addr-line>Palo Alto, CA</addr-line>, <country>USA</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Jan Hau Lee, KK Women’s and Children’s Hospital, Singapore</p></fn><fn fn-type="edited-by"><p>Reviewed by: Christine Uta Vohwinkel, University of Colorado Denver Medical School, USA; Jerry John Zimmerman, Seattle Children’s Hospital and University of Washington School of Medicine, USA</p></fn><corresp content-type="corresp" id="cor1">*Correspondence: Dai Kimura, <email>dkimura@uthsc.edu</email></corresp><fn fn-type="other" id="fn001"><p>Specialty section: This article was submitted to Pediatric Critical Care, a section of the journal Frontiers in Pediatrics</p></fn></author-notes><pub-date pub-type="epub"><day>31</day><month>3</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>4</volume><elocation-id>31</elocation-id><history><date date-type="received"><day>08</day><month>1</month><year>2016</year></date><date date-type="accepted"><day>21</day><month>3</month><year>2016</year></date></history><permissions><copyright-statement>Copyright © 2016 Kimura, Saravia, Rovnaghi, Meduri, Schwingshackl, Cormier and Anand.</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Kimura, Saravia, Rovnaghi, Meduri, Schwingshackl, Cormier and Anand</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract abstract-type="executive-summary"><sec id="ST1"><title><offsets xml_i="7697" xml_f="7706" txt_i="11" txt_f="20">Objective</offsets></title><p><offsets xml_i="7717" xml_f="8405" txt_i="21" txt_f="709">Lung injury activates multiple pro-inflammatory pathways, including neutrophils, epithelial, and endothelial injury, and coagulation factors leading to acute respiratory distress syndrome (ARDS). Low-dose methylprednisolone therapy (MPT) improved oxygenation and ventilation in early pediatric ARDS without altering duration of mechanical ventilation or mortality. We evaluated the effects of MPT on biomarkers of endothelial [Ang-2 and soluble intercellular adhesion molecule-1 (sICAM-1)] or epithelial [soluble receptor for activated glycation end products (sRAGE)] injury, neutrophil activation [matrix metalloproteinase-8 (MMP-8)], and coagulation (plasminogen activator inhibitor-1).</offsets></p></sec><sec id="ST2"><title><offsets xml_i="8436" xml_f="8442" txt_i="711" txt_f="717">Design</offsets></title><p><offsets xml_i="8453" xml_f="8503" txt_i="718" txt_f="768">Double-blind, placebo-controlled randomized trial.</offsets></p></sec><sec id="ST3"><title><offsets xml_i="8534" xml_f="8541" txt_i="770" txt_f="777">Setting</offsets></title><p><offsets xml_i="8552" xml_f="8602" txt_i="778" txt_f="828">Tertiary-care pediatric intensive care unit (ICU).</offsets></p></sec><sec id="ST4"><title><offsets xml_i="8633" xml_f="8641" txt_i="830" txt_f="838">Patients</offsets></title><p><offsets xml_i="8652" xml_f="8714" txt_i="839" txt_f="901">Mechanically ventilated children (0–18 years) with early ARDS.</offsets></p></sec><sec id="ST5"><title><offsets xml_i="8745" xml_f="8758" txt_i="903" txt_f="916">Interventions</offsets></title><p><offsets xml_i="8769" xml_f="8853" txt_i="917" txt_f="1001">Blood samples were collected on days 0 (before MPT), 7, and 14 during low-dose MPT (</offsets><italic><offsets xml_i="8861" xml_f="8862" txt_i="1001" txt_f="1002">n</offsets></italic><offsets xml_i="8871" xml_f="8891" txt_i="1002" txt_f="1022"> = 17) vs. placebo (</offsets><italic><offsets xml_i="8899" xml_f="8900" txt_i="1022" txt_f="1023">n</offsets></italic><offsets xml_i="8909" xml_f="9414" txt_i="1023" txt_f="1528"> = 18) therapy. The MPT group received a 2-mg/kg loading dose followed by 1 mg/kg/day continuous infusions from days 1 to 7, tapered off over 7 days; placebo group received equivalent amounts of 0.9% saline. We analyzed plasma samples using a multiplex assay for five biomarkers of ARDS. Multiple regression models were constructed to predict associations between changes in biomarkers and the clinical outcomes reported earlier, including P/F ratio on days 8 and 9, plateau pressure on days 1 and 2, PaCO</offsets><sub><offsets xml_i="9419" xml_f="9420" txt_i="1528" txt_f="1529">2</offsets></sub><offsets xml_i="9426" xml_f="9527" txt_i="1529" txt_f="1630"> on days 2 and 3, racemic epinephrine following extubation, and supplemental oxygen at ICU discharge.</offsets></p></sec><sec id="ST6"><title><offsets xml_i="9558" xml_f="9565" txt_i="1632" txt_f="1639">Results</offsets></title><p><offsets xml_i="9576" xml_f="9694" txt_i="1640" txt_f="1758">No differences occurred in biomarker concentrations between the groups on day 0. On day 7, reduction in MMP-8 levels (</offsets><italic><offsets xml_i="9702" xml_f="9703" txt_i="1758" txt_f="1759">p</offsets></italic><offsets xml_i="9712" xml_f="9787" txt_i="1759" txt_f="1834"> = 0.0016) occurred in the MPT group, whereas increases in sICAM-1 levels (</offsets><italic><offsets xml_i="9795" xml_f="9796" txt_i="1834" txt_f="1835">p</offsets></italic><offsets xml_i="9805" xml_f="9945" txt_i="1835" txt_f="1975"> = 0.0005) occurred in the placebo group (no increases in sICAM-1 in the MPT group). sRAGE levels decreased in both MPT and placebo groups (</offsets><italic><offsets xml_i="9953" xml_f="9954" txt_i="1975" txt_f="1976">p</offsets></italic><offsets xml_i="9963" xml_f="10066" txt_i="1976" txt_f="2076"> &lt; 0.0001) from day 0 to day 7. On day 7, sRAGE levels were positively correlated with MPT group PaO</offsets><sub><offsets xml_i="10071" xml_f="10072" txt_i="2076" txt_f="2077">2</offsets></sub><offsets xml_i="10078" xml_f="10082" txt_i="2077" txt_f="2081">/FiO</offsets><sub><offsets xml_i="10087" xml_f="10088" txt_i="2081" txt_f="2082">2</offsets></sub><offsets xml_i="10094" xml_f="10112" txt_i="2082" txt_f="2100"> ratios on day 8 (</offsets><italic><offsets xml_i="10120" xml_f="10121" txt_i="2100" txt_f="2101">r</offsets></italic><offsets xml_i="10130" xml_f="10139" txt_i="2101" txt_f="2110"> = 0.93, </offsets><italic><offsets xml_i="10147" xml_f="10148" txt_i="2110" txt_f="2111">p</offsets></italic><offsets xml_i="10157" xml_f="10169" txt_i="2111" txt_f="2123"> = 0.024). O</offsets><sub><offsets xml_i="10174" xml_f="10175" txt_i="2123" txt_f="2124">2</offsets></sub><offsets xml_i="10181" xml_f="10251" txt_i="2124" txt_f="2194"> requirements at ICU transfer positively correlated with day 7 MMP-8 (</offsets><italic><offsets xml_i="10259" xml_f="10260" txt_i="2194" txt_f="2195">r</offsets></italic><offsets xml_i="10269" xml_f="10278" txt_i="2195" txt_f="2204"> = 0.85, </offsets><italic><offsets xml_i="10286" xml_f="10287" txt_i="2204" txt_f="2205">p</offsets></italic><offsets xml_i="10296" xml_f="10324" txt_i="2205" txt_f="2233"> = 0.016) and Ang-2 levels (</offsets><italic><offsets xml_i="10332" xml_f="10333" txt_i="2233" txt_f="2234">r</offsets></italic><offsets xml_i="10342" xml_f="10351" txt_i="2234" txt_f="2243"> = 0.79, </offsets><italic><offsets xml_i="10359" xml_f="10360" txt_i="2243" txt_f="2244">p</offsets></italic><offsets xml_i="10369" xml_f="10452" txt_i="2244" txt_f="2327"> = 0.036) in the placebo group and inversely correlated with day 7 sICAM-1 levels (</offsets><italic><offsets xml_i="10460" xml_f="10461" txt_i="2327" txt_f="2328">r</offsets></italic><offsets xml_i="10470" xml_f="10480" txt_i="2328" txt_f="2338"> = −0.91, </offsets><italic><offsets xml_i="10488" xml_f="10489" txt_i="2338" txt_f="2339">p</offsets></italic><offsets xml_i="10498" xml_f="10525" txt_i="2339" txt_f="2366"> = 0.005) in the MPT group.</offsets></p></sec><sec id="ST7"><title><offsets xml_i="10556" xml_f="10566" txt_i="2368" txt_f="2378">Conclusion</offsets></title><p><offsets xml_i="10577" xml_f="10916" txt_i="2379" txt_f="2718">Biomarkers selected from endothelial, epithelial, or intravascular factors can be correlated with clinical endpoints in pediatric ARDS. For example, MPT could reduce neutrophil activation (⇓MMP-8), decrease endothelial injury (⇔sICAM-1), and allow epithelial recovery (⇓sRAGE). Large ARDS clinical trials should develop similar frameworks.</offsets></p></sec><sec id="ST8"><title><offsets xml_i="10947" xml_f="10965" txt_i="2720" txt_f="2738">Trial Registration</offsets></title><p><uri xlink:type="simple" xlink:href="https://clinicaltrials.gov"><offsets xml_i="11041" xml_f="11067" txt_i="2739" txt_f="2765">https://clinicaltrials.gov</offsets></uri><offsets xml_i="11073" xml_f="11087" txt_i="2765" txt_f="2779">, NCT01274260.</offsets></p></sec></abstract><kwd-group><kwd>ARDS</kwd><kwd>biomarker</kwd><kwd>pediatric</kwd><kwd>methylprednisolone</kwd><kwd>MMP-8</kwd><kwd>Ang-2</kwd><kwd>ICAM-1</kwd><kwd>sRAGE</kwd></kwd-group><funding-group><award-group><funding-source id="cn01">National Institutes of Health<named-content content-type="fundref-id">10.13039/100000002</named-content></funding-source><award-id rid="cn01">7KO8HL118118-03, R01AI090059, R01ES015050, P42ES013648</award-id></award-group><award-group><funding-source id="cn02">Le Bonheur Foundation grant</funding-source><award-id rid="cn02">641003</award-id></award-group></funding-group><counts><fig-count count="1"></fig-count><table-count count="2"></table-count><equation-count count="0"></equation-count><ref-count count="41"></ref-count><page-count count="8"></page-count><word-count count="6144"></word-count></counts></article-meta></front><body><sec id="S1"><title><offsets xml_i="11992" xml_f="12002" txt_i="2788" txt_f="2798">Background</offsets></title><p><offsets xml_i="12013" xml_f="12200" txt_i="2799" txt_f="2986">The pathogenesis of acute respiratory distress syndrome (ARDS) may result from dysregulated inflammation in the endothelial and epithelial spaces from pulmonary or systemic circulations (</offsets><xref rid="B1" ref-type="bibr"><offsets xml_i="12231" xml_f="12232" txt_i="2986" txt_f="2987">1</offsets></xref><offsets xml_i="12239" xml_f="12488" txt_i="2987" txt_f="3236">). ARDS is associated with alveolar and interstitial edema, infiltration of inflammatory cells (neutrophils and macrophages) into the alveolar space due to vascular permeability, abnormal coagulation, and endothelial and alveolar epithelial injury (</offsets><xref rid="B1" ref-type="bibr"><offsets xml_i="12519" xml_f="12520" txt_i="3236" txt_f="3237">1</offsets></xref><offsets xml_i="12527" xml_f="12637" txt_i="3237" txt_f="3347">). Corticosteroids may suppress this dysregulated inflammation in ARDS and thereby improve clinical outcomes (</offsets><xref rid="B2" ref-type="bibr"><offsets xml_i="12668" xml_f="12669" txt_i="3347" txt_f="3348">2</offsets></xref><offsets xml_i="12676" xml_f="12774" txt_i="3348" txt_f="3446">). In adult patients with ARDS, early low-dose corticosteroid treatment showed promising results (</offsets><xref rid="B3" ref-type="bibr"><offsets xml_i="12805" xml_f="12806" txt_i="3446" txt_f="3447">3</offsets></xref><offsets xml_i="12813" xml_f="13167" txt_i="3447" txt_f="3801">). However, the American College of Critical Care Medicine recommends the use of corticosteroids only for adult patients with moderate to severe ARDS resulting from community-acquired pneumonia (grade 2B). A single-center retrospective study reported that utilization of corticosteroids in pediatric ARDS was associated with worsening clinical outcomes (</offsets><xref rid="B4" ref-type="bibr"><offsets xml_i="13198" xml_f="13199" txt_i="3801" txt_f="3802">4</offsets></xref><offsets xml_i="13206" xml_f="13407" txt_i="3802" txt_f="4003">). However, this study did not record the indications for corticosteroid administration and neither considered the length of therapy nor the need for tapering steroids to prevent rebound inflammation (</offsets><xref rid="B5" ref-type="bibr"><offsets xml_i="13438" xml_f="13439" txt_i="4003" txt_f="4004">5</offsets></xref><offsets xml_i="13446" xml_f="13448" txt_i="4004" txt_f="4006">).</offsets></p><p><offsets xml_i="13455" xml_f="13614" txt_i="4007" txt_f="4166">We published the first pilot randomized trial of low-dose methylprednisolone therapy (MPT) for early pediatric ARDS examining the feasibility of this therapy (</offsets><xref rid="B6" ref-type="bibr"><offsets xml_i="13645" xml_f="13646" txt_i="4166" txt_f="4167">6</offsets></xref><offsets xml_i="13653" xml_f="13718" txt_i="4167" txt_f="4232">). We modified the protocol for administering MPT in adult ARDS (</offsets><xref rid="B3" ref-type="bibr"><offsets xml_i="13749" xml_f="13750" txt_i="4232" txt_f="4233">3</offsets></xref><offsets xml_i="13757" xml_f="13947" txt_i="4233" txt_f="4423">), which includes the slow tapering of MPT dosage over 1 week to avoid rebound lung inflammation and systemic inflammatory response syndrome (SIRS) leading to recurrent respiratory failure (</offsets><xref rid="B7" ref-type="bibr"><offsets xml_i="13978" xml_f="13979" txt_i="4423" txt_f="4424">7</offsets></xref><offsets xml_i="13986" xml_f="14100" txt_i="4424" txt_f="4538">). MPT therapy did not alter ventilator-free days or mortality but appeared to alter oxygenation and ventilation (</offsets><xref rid="B6" ref-type="bibr"><offsets xml_i="14131" xml_f="14132" txt_i="4538" txt_f="4539">6</offsets></xref><offsets xml_i="14139" xml_f="14380" txt_i="4539" txt_f="4780">). We also examined different regulatory patterns of pro- and anti-inflammatory plasma cytokines in the MPT and placebo groups to identify several cytokines as potential predictors for alterations in clinical parameters of disease severity (</offsets><xref rid="B8" ref-type="bibr"><offsets xml_i="14411" xml_f="14412" txt_i="4780" txt_f="4781">8</offsets></xref><offsets xml_i="14419" xml_f="14534" txt_i="4781" txt_f="4896">). Larger randomized controlled studies are warranted for investigating corticosteroid use in early pediatric ARDS.</offsets></p><p><offsets xml_i="14541" xml_f="14606" txt_i="4897" txt_f="4962">Corticosteroids are widely used in pediatric patients with ARDS (</offsets><xref rid="B4" ref-type="bibr"><offsets xml_i="14637" xml_f="14638" txt_i="4962" txt_f="4963">4</offsets></xref><offsets xml_i="14645" xml_f="15202" txt_i="4963" txt_f="5520">), but their effects on biomarker levels in ARDS remain unknown. We selected five plasma biomarkers signifying the endothelial [Ang-2 and soluble intercellular adhesion molecule-1 (sICAM-1)], epithelial [soluble receptor for activated glycation end products (sRAGE)], coagulation [plasminogen activator inhibitor (PAI-1)], and neutrophil [matrix metalloproteinase-8 (MMP-8)] factors contributing to the pathogenesis of ARDS. The main purpose of this pilot study was to generate a potential framework for studying ARDS pathogenesis in future clinical trials.</offsets></p></sec><sec sec-type="materials|methods" id="S2"><title><offsets xml_i="15261" xml_f="15282" txt_i="5522" txt_f="5543">Materials and Methods</offsets></title><sec id="S2-1"><title><offsets xml_i="15312" xml_f="15326" txt_i="5544" txt_f="5558">Clinical Trial</offsets></title><p><offsets xml_i="15337" xml_f="15390" txt_i="5559" txt_f="5612">A double-blind, placebo-controlled randomized trial (</offsets><uri xlink:type="simple" xlink:href="https://clinicaltrial.gov"><offsets xml_i="15454" xml_f="15479" txt_i="5612" txt_f="5637">https://clinicaltrial.gov</offsets></uri><offsets xml_i="15485" xml_f="15609" txt_i="5637" txt_f="5761">, NCT01274260) was conducted in pediatric intensive care unit (PICU) in Le Bonheur children’s hospital in Memphis, TN, USA (</offsets><xref rid="B6" ref-type="bibr"><offsets xml_i="15640" xml_f="15641" txt_i="5761" txt_f="5762">6</offsets></xref><offsets xml_i="15648" xml_f="16346" txt_i="5762" txt_f="6457">). The Institutional Review Board of University of Tennessee Health Science Center approved this study. Children (0–18 years) fulfilling the Berlin definition of ARDS and receiving mechanical ventilation were included in the study after informed consent. Patients receiving glucocorticoids chronically, terminally ill or in hospice care, immunosuppressed, with extensive burns, adrenal insufficiency, vasculitis, diffuse alveolar hemorrhage, invasive fungal infection, chronic liver disease or gastrointestinal bleed within the past 1 month, or conditions with estimated 6-month mortality of &gt;50% were excluded from the study. The patients were randomized into low-dose methylprednisolone (MPT, </offsets><italic><offsets xml_i="16354" xml_f="16355" txt_i="6457" txt_f="6458">n</offsets></italic><offsets xml_i="16364" xml_f="16397" txt_i="6458" txt_f="6491"> = 17, and no death) or placebo (</offsets><italic><offsets xml_i="16405" xml_f="16406" txt_i="6491" txt_f="6492">n</offsets></italic><offsets xml_i="16415" xml_f="16729" txt_i="6492" txt_f="6806"> = 18 and two deaths) group. There were no significant differences in baseline characteristics including age, weight, gender, race, pediatric risk of mortality (PRISM) III score, pediatric index of mortality-2 score, P/F ratio, PEEP, tidal volume (milliliter per kilogram), mean airway pressure, blood gas pH, PaCO</offsets><sub><offsets xml_i="16734" xml_f="16735" txt_i="6806" txt_f="6807">2</offsets></sub><offsets xml_i="16741" xml_f="16864" txt_i="6807" txt_f="6930">, and the number of lobes affected on chest X-ray. Only exceptions were higher plateau pressure of mechanical ventilation (</offsets><italic><offsets xml_i="16872" xml_f="16873" txt_i="6930" txt_f="6931">p</offsets></italic><offsets xml_i="16882" xml_f="16947" txt_i="6931" txt_f="6996"> = 0.006) and lower pediatric logistic organ dysfunction scores (</offsets><italic><offsets xml_i="16955" xml_f="16956" txt_i="6996" txt_f="6997">p</offsets></italic><offsets xml_i="16965" xml_f="17942" txt_i="6997" txt_f="7971"> = 0.04) in the MPT group. The causes of ARDS were mainly primary ARDS (&gt;3/4 of the patients in both groups). The most common cause was pneumonia (12 in MPT and 7 in the placebo), followed by aspiration (5 in MPT and 7 in the placebo), bronchiolitis (4 in MPT and 3 in the placebo), and near drowning (2 in MPT and 2 in the placebo). The patients in the MPT group received a 2 mg/kg MPT loading dose within 72 h after diagnosis of ARDS, followed by a 1 mg/kg/day continuous infusion from days 1 to 7, then tapered off over 7 days. If patients were extubated before day 7, the dosage protocol was advanced to day 7 followed by tapering. Patients were ventilated according to ARDSnet recommendations modified for children using pressure regulated volume control mode of Servo-i ventilators (Maquet) set at tidal volume of 6–8 ml/kg (ideal body weight if the patient is obese). All the patients finished the study. Two patients died in the placebo group and no one in the MPT (</offsets><italic><offsets xml_i="17950" xml_f="17951" txt_i="7971" txt_f="7972">p</offsets></italic><offsets xml_i="17960" xml_f="18084" txt_i="7972" txt_f="8096"> = 0.15). The duration of mechanical ventilation was 9.74 ± 6.62 days in the placebo group and 9.59 ± 5.21 days in the MPT (</offsets><italic><offsets xml_i="18092" xml_f="18093" txt_i="8096" txt_f="8097">p</offsets></italic><offsets xml_i="18102" xml_f="18281" txt_i="8097" txt_f="8276"> = 0.94). There were no significant differences in ventilator-free days or length of stay in intensive care unit (ICU) or hospital between the groups. The MPT group had lower PaCO</offsets><sub><offsets xml_i="18286" xml_f="18287" txt_i="8276" txt_f="8277">2</offsets></sub><offsets xml_i="18293" xml_f="18348" txt_i="8277" txt_f="8332"> values on days 2 and 3, higher pH on day 2, higher PaO</offsets><sub><offsets xml_i="18353" xml_f="18354" txt_i="8332" txt_f="8333">2</offsets></sub><offsets xml_i="18360" xml_f="18364" txt_i="8333" txt_f="8337">/FiO</offsets><sub><offsets xml_i="18369" xml_f="18370" txt_i="8337" txt_f="8338">2</offsets></sub><offsets xml_i="18376" xml_f="18702" txt_i="8338" txt_f="8664"> ratios on days 8 and 9, fewer patients required racemic epinephrine inhalation treatment for post-extubation stridor, and fewer patients required supplemental oxygen at ICU transfer. MPT was not associated with any adverse effects, including secondary bacterial infection, hyperglycemia, and hypertension monitored regularly.</offsets></p></sec><sec id="S2-2"><title><offsets xml_i="18734" xml_f="18748" txt_i="8666" txt_f="8680">Plasma Samples</offsets></title><p><offsets xml_i="18759" xml_f="19009" txt_i="8681" txt_f="8931">Blood samples were collected in lavender-top, EDTA-containing tubes at day 0 (before steroid administration) and day 7 during the randomized control trial. The blood samples were transported to our hospital central laboratory, centrifuged at 1,000 × </offsets><italic><offsets xml_i="19017" xml_f="19018" txt_i="8931" txt_f="8932">g</offsets></italic><offsets xml_i="19027" xml_f="19078" txt_i="8932" txt_f="8983"> for 10 min at 4°C, and stored at −80°C until used.</offsets></p></sec><sec id="S2-3"><title><offsets xml_i="19110" xml_f="19128" txt_i="8985" txt_f="9003">Biomarker Analysis</offsets></title><p><offsets xml_i="19139" xml_f="19900" txt_i="9004" txt_f="9765">We analyzed these plasma samples for MMP-8, Ang-2, PAI-1, sICAM-1, and sRAGE using a multiplex assay (Millipore, Billerica, MA, USA, cat#HSP4MAG-63K, #HAGP1MAG-12K, #HSP1MAG-63K, #HSCRMAG-32K), according to the manufacturer’s instructions. A standard curve was prepared over concentrations of 0.14–100 ng/ml for MMP-8, 13.7–10,000 pg/ml for Ang-2, 12–50,000 pg/ml for PAI-1 and sRAGE, and 60–250,000 pg/ml for sICAM-1. All samples were run in duplicates, and the average concentrations were used for statistical analysis. Only a few samples showed the biomarker values below or above the limit of the standard curve (two samples were above the limit on day 0 and one sample on day 7 below the limit for MMP-8. One sample on day 7 was below the limit for sRAGE).</offsets></p></sec><sec id="S2-4"><title><offsets xml_i="19932" xml_f="19952" txt_i="9767" txt_f="9787">Statistical Analysis</offsets></title><p><offsets xml_i="19963" xml_f="20078" txt_i="9788" txt_f="9903">We used univariate (descriptive statistics and frequency distributions), bivariate (Fisher’s test for variability, </offsets><italic><offsets xml_i="20086" xml_f="20087" txt_i="9903" txt_f="9904">t</offsets></italic><offsets xml_i="20096" xml_f="20653" txt_i="9904" txt_f="10461">-tests, and Pearson’s correlations), and multivariate analyses (multivariate linear regressions using the least squares method) to evaluate the effects of MPT in pediatric ARDS. We used StatPlus (AnalystSoft, Inc.) for generating descriptive statistics and frequency distributions for all biomarker levels at days 0 and 7 for the placebo and MPT groups. We used Prism 6 (GraphPad Software, Inc.) for comparing between the randomized groups at days 0 and 7, and comparing between days 0 and 7 within the MPT or placebo groups. Either the unpaired two-tailed </offsets><italic><offsets xml_i="20661" xml_f="20662" txt_i="10461" txt_f="10462">t</offsets></italic><offsets xml_i="20671" xml_f="20710" txt_i="10462" txt_f="10501">-test (parametric) or the Mann–Whitney </offsets><italic><offsets xml_i="20718" xml_f="20719" txt_i="10501" txt_f="10502">U</offsets></italic><offsets xml_i="20728" xml_f="20822" txt_i="10502" txt_f="10596"> test (non-parametric) was used for group comparisons, after comparing their variances by the </offsets><italic><offsets xml_i="20830" xml_f="20831" txt_i="10596" txt_f="10597">F</offsets></italic><offsets xml_i="20840" xml_f="20846" txt_i="10597" txt_f="10603"> test.</offsets></p><p><offsets xml_i="20853" xml_f="20979" txt_i="10604" txt_f="10730">A correlation matrix for pairwise associations of Pearson correlation coefficients was also generated with simultaneously run </offsets><italic><offsets xml_i="20987" xml_f="20988" txt_i="10730" txt_f="10731">t</offsets></italic><offsets xml_i="20997" xml_f="21126" txt_i="10731" txt_f="10860">-tests for pathway analysis of the measured mediators. We used pairs of variables demonstrating strong correlation coefficients (</offsets><italic><offsets xml_i="21134" xml_f="21135" txt_i="10860" txt_f="10861">R</offsets></italic><offsets xml_i="21144" xml_f="21152" txt_i="10861" txt_f="10869"> ≥ 0.7, </offsets><italic><offsets xml_i="21160" xml_f="21161" txt_i="10869" txt_f="10870">p</offsets></italic><offsets xml_i="21170" xml_f="21274" txt_i="10870" txt_f="10974"> ≤ 0.01) to build multivariate regression models for predicting the clinical outcomes reported earlier (</offsets><xref rid="B6" ref-type="bibr"><offsets xml_i="21305" xml_f="21306" txt_i="10974" txt_f="10975">6</offsets></xref><offsets xml_i="21313" xml_f="21327" txt_i="10975" txt_f="10989">), namely, PaO</offsets><sub><offsets xml_i="21332" xml_f="21333" txt_i="10989" txt_f="10990">2</offsets></sub><offsets xml_i="21339" xml_f="21343" txt_i="10990" txt_f="10994">/FiO</offsets><sub><offsets xml_i="21348" xml_f="21349" txt_i="10994" txt_f="10995">2</offsets></sub><offsets xml_i="21355" xml_f="21423" txt_i="10995" txt_f="11063"> (P/F) ratio on days 8 and 9, plateau pressure on days 1 and 2, PaCO</offsets><sub><offsets xml_i="21428" xml_f="21429" txt_i="11063" txt_f="11064">2</offsets></sub><offsets xml_i="21435" xml_f="21544" txt_i="11064" txt_f="11173"> on days 2 and 3, need for racemic epinephrine following extubation, or supplemental oxygen at ICU discharge.</offsets></p><p><offsets xml_i="21551" xml_f="22134" txt_i="11174" txt_f="11757">We created bivariate correlation matrices and bar graphs using raw data without adjustment or imputation. Rarely, imputation of missing biomarker values was necessary to build the multivariate regression models explaining or contributing to glucocorticoid treatment-associated clinical outcomes. Biomarker values falling above or below the extreme values of the standard curve were assigned the highest or lowest values on the generated standard curve. Since these were exploratory, hypothesis-generating analyses, we did not make corrections for multiple comparisons between groups.</offsets></p></sec></sec><sec id="S3"><title><offsets xml_i="22170" xml_f="22177" txt_i="11760" txt_f="11767">Results</offsets></title><sec id="S3-1"><title><offsets xml_i="22207" xml_f="22269" txt_i="11768" txt_f="11830">Baseline and Time-Dependent Changes in Plasma Biomarker Levels</offsets></title><p><offsets xml_i="22280" xml_f="22491" txt_i="11831" txt_f="12042">No differences occurred in the baseline concentrations of plasma biomarkers between the placebo and MPT groups on day 0 or on day 7. Within group, comparisons showed that MMP-8 levels decreased from day 0 to 7 (</offsets><italic><offsets xml_i="22499" xml_f="22500" txt_i="12042" txt_f="12043">p</offsets></italic><offsets xml_i="22509" xml_f="22624" txt_i="12043" txt_f="12158"> = 0.0016) in the MPT group, but not in the placebo group. sICAM-1 levels increased significantly from day 0 to 7 (</offsets><italic><offsets xml_i="22632" xml_f="22633" txt_i="12158" txt_f="12159">p</offsets></italic><offsets xml_i="22642" xml_f="22756" txt_i="12159" txt_f="12273"> = 0.0005) in the placebo group, but not in the MPT group. sRAGE levels decreased in both MPT and placebo groups (</offsets><italic><offsets xml_i="22764" xml_f="22765" txt_i="12273" txt_f="12274">p</offsets></italic><offsets xml_i="22774" xml_f="22815" txt_i="12274" txt_f="12312"> &lt; 0.0001) from day 0 to day 7 (Table </offsets><xref ref-type="table" rid="T1"><offsets xml_i="22847" xml_f="22848" txt_i="12312" txt_f="12313">1</offsets></xref><offsets xml_i="22855" xml_f="22928" txt_i="12313" txt_f="12386">). No significant differences occurred in Ang-2 and PAI-1 levels (Figure </offsets><xref ref-type="fig" rid="F1"><offsets xml_i="22958" xml_f="22959" txt_i="12386" txt_f="12387">1</offsets></xref><offsets xml_i="22966" xml_f="22968" txt_i="12387" txt_f="12389">).</offsets></p><table-wrap id="T1" position="float"><label><offsets xml_i="23016" xml_f="23023" txt_i="12390" txt_f="12397">Table 1</offsets></label><caption><p><bold><offsets xml_i="23049" xml_f="23163" txt_i="12397" txt_f="12511">Significant results from comparison of biomarker levels within the placebo and the MPT groups between days 0 and 7</offsets></bold><offsets xml_i="23170" xml_f="23171" txt_i="12511" txt_f="12512">.</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="bottom" align="left" rowspan="1" colspan="1"></th><th valign="bottom" align="center" rowspan="1" colspan="1"><italic><offsets xml_i="23362" xml_f="23363" txt_i="12513" txt_f="12514">N</offsets></italic></th><th valign="bottom" align="center" rowspan="1" colspan="1"><offsets xml_i="23436" xml_f="23442" txt_i="12514" txt_f="12520">Median</offsets></th><th valign="bottom" align="center" rowspan="1" colspan="1"><offsets xml_i="23506" xml_f="23520" txt_i="12520" txt_f="12534">25% percentile</offsets></th><th valign="bottom" align="center" rowspan="1" colspan="1"><offsets xml_i="23584" xml_f="23598" txt_i="12534" txt_f="12548">75% percentile</offsets></th><th valign="bottom" align="center" rowspan="1" colspan="1"><offsets xml_i="23662" xml_f="23666" txt_i="12548" txt_f="12552">Mean</offsets></th><th valign="bottom" align="center" rowspan="1" colspan="1"><offsets xml_i="23730" xml_f="23732" txt_i="12552" txt_f="12554">SD</offsets></th><th valign="bottom" align="center" rowspan="1" colspan="1"><offsets xml_i="23796" xml_f="23799" txt_i="12554" txt_f="12557">SEM</offsets></th><th valign="bottom" align="center" rowspan="1" colspan="1"><offsets xml_i="23863" xml_f="23886" txt_i="12557" txt_f="12580">Two-tailed Mann–Whitney</offsets></th><th valign="bottom" align="center" rowspan="1" colspan="1"><offsets xml_i="23950" xml_f="23970" txt_i="12580" txt_f="12600">Two-tailed unpaired </offsets><italic><offsets xml_i="23978" xml_f="23979" txt_i="12600" txt_f="12601">t</offsets></italic><offsets xml_i="23988" xml_f="23993" txt_i="12601" txt_f="12606">-test</offsets></th></tr></thead><tbody><tr><td align="left" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="24079" xml_f="24104" txt_i="12606" txt_f="12631">MPT, day 0: MMP-8 (ng/ml)</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="24168" xml_f="24170" txt_i="12632" txt_f="12634">15</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="24234" xml_f="24236" txt_i="12635" txt_f="12637">12</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="24300" xml_f="24303" txt_i="12638" txt_f="12641">6.4</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="24367" xml_f="24369" txt_i="12642" txt_f="12644">23</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="24433" xml_f="24435" txt_i="12645" txt_f="12647">20</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="24499" xml_f="24501" txt_i="12648" txt_f="12650">25</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="24565" xml_f="24568" txt_i="12651" txt_f="12654">6.3</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="24632" xml_f="24638" txt_i="12655" txt_f="12661">0.0016</offsets></td><td align="left" valign="bottom" rowspan="1" colspan="1"></td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="24771" xml_f="24796" txt_i="12663" txt_f="12688">MPT, day 7: MMP-8 (ng/ml)</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="24860" xml_f="24861" txt_i="12689" txt_f="12690">6</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="24925" xml_f="24929" txt_i="12691" txt_f="12695">0.63</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="24993" xml_f="24997" txt_i="12696" txt_f="12700">0.28</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="25061" xml_f="25064" txt_i="12701" txt_f="12704">4.8</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="25128" xml_f="25131" txt_i="12705" txt_f="12708">2.1</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="25195" xml_f="25198" txt_i="12709" txt_f="12712">2.7</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="25262" xml_f="25265" txt_i="12713" txt_f="12716">1.1</offsets></td><td align="left" valign="bottom" rowspan="1" colspan="1"></td><td align="left" valign="bottom" rowspan="1" colspan="1"></td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="25460" xml_f="25485" txt_i="12719" txt_f="12744">MPT, day 0: sRAGE (pg/ml)</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="25549" xml_f="25551" txt_i="12745" txt_f="12747">15</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="25615" xml_f="25618" txt_i="12748" txt_f="12751">356</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="25682" xml_f="25685" txt_i="12752" txt_f="12755">244</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="25749" xml_f="25752" txt_i="12756" txt_f="12759">535</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="25816" xml_f="25821" txt_i="12760" txt_f="12765">1,085</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="25885" xml_f="25890" txt_i="12766" txt_f="12771">2,495</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="25954" xml_f="25957" txt_i="12772" txt_f="12775">644</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="26021" xml_f="26027" txt_i="12776" txt_f="12782">0.0007</offsets></td><td align="left" valign="bottom" rowspan="1" colspan="1"></td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="26160" xml_f="26185" txt_i="12784" txt_f="12809">MPT, day 7: sRAGE (pg/ml)</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="26249" xml_f="26250" txt_i="12810" txt_f="12811">6</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="26314" xml_f="26316" txt_i="12812" txt_f="12814">74</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="26380" xml_f="26382" txt_i="12815" txt_f="12817">16</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="26446" xml_f="26449" txt_i="12818" txt_f="12821">136</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="26513" xml_f="26515" txt_i="12822" txt_f="12824">79</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="26579" xml_f="26581" txt_i="12825" txt_f="12827">62</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="26645" xml_f="26647" txt_i="12828" txt_f="12830">25</offsets></td><td align="left" valign="bottom" rowspan="1" colspan="1"></td><td align="left" valign="bottom" rowspan="1" colspan="1"></td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="26842" xml_f="26866" txt_i="12833" txt_f="12857">P, day 0: ICAM-1 (pg/ml)</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="26930" xml_f="26932" txt_i="12858" txt_f="12860">18</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="26996" xml_f="27002" txt_i="12861" txt_f="12867">13,814</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="27066" xml_f="27071" txt_i="12868" txt_f="12873">8,444</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="27135" xml_f="27141" txt_i="12874" txt_f="12880">17,783</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="27205" xml_f="27211" txt_i="12881" txt_f="12887">13,973</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="27275" xml_f="27280" txt_i="12888" txt_f="12893">5,453</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="27344" xml_f="27349" txt_i="12894" txt_f="12899">1,285</offsets></td><td align="left" valign="bottom" rowspan="1" colspan="1"></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="27475" xml_f="27481" txt_i="12901" txt_f="12907">0.0005</offsets></td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="27552" xml_f="27576" txt_i="12908" txt_f="12932">P, day 7: ICAM-1 (pg/ml)</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="27640" xml_f="27641" txt_i="12933" txt_f="12934">7</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="27705" xml_f="27711" txt_i="12935" txt_f="12941">24,824</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="27775" xml_f="27781" txt_i="12942" txt_f="12948">16,710</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="27845" xml_f="27851" txt_i="12949" txt_f="12955">30,346</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="27915" xml_f="27921" txt_i="12956" txt_f="12962">24,461</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="27985" xml_f="27990" txt_i="12963" txt_f="12968">6,859</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="28054" xml_f="28059" txt_i="12969" txt_f="12974">2,592</offsets></td><td align="left" valign="bottom" rowspan="1" colspan="1"></td><td align="left" valign="bottom" rowspan="1" colspan="1"></td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="28254" xml_f="28277" txt_i="12977" txt_f="13000">P, day 0: sRAGE (pg/ml)</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="28341" xml_f="28343" txt_i="13001" txt_f="13003">18</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="28407" xml_f="28410" txt_i="13004" txt_f="13007">376</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="28474" xml_f="28477" txt_i="13008" txt_f="13011">152</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="28541" xml_f="28546" txt_i="13012" txt_f="13017">2,941</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="28610" xml_f="28615" txt_i="13018" txt_f="13023">1,599</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="28679" xml_f="28684" txt_i="13024" txt_f="13029">2,346</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="28748" xml_f="28751" txt_i="13030" txt_f="13033">553</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="28815" xml_f="28821" txt_i="13034" txt_f="13040">0.0018</offsets></td><td align="left" valign="bottom" rowspan="1" colspan="1"></td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="28954" xml_f="28977" txt_i="13042" txt_f="13065">P, day 7: sRAGE (pg/ml)</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="29041" xml_f="29042" txt_i="13066" txt_f="13067">7</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="29106" xml_f="29108" txt_i="13068" txt_f="13070">77</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="29172" xml_f="29174" txt_i="13071" txt_f="13073">29</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="29238" xml_f="29241" txt_i="13074" txt_f="13077">131</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="29305" xml_f="29307" txt_i="13078" txt_f="13080">79</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="29371" xml_f="29373" txt_i="13081" txt_f="13083">49</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="29437" xml_f="29439" txt_i="13084" txt_f="13086">19</offsets></td><td align="left" valign="bottom" rowspan="1" colspan="1"></td><td align="left" valign="bottom" rowspan="1" colspan="1"></td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="29634" xml_f="29659" txt_i="13089" txt_f="13114">A-S, day 0: MMP-8 (ng/ml)</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="29723" xml_f="29725" txt_i="13115" txt_f="13117">32</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="29789" xml_f="29791" txt_i="13118" txt_f="13120">10</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="29855" xml_f="29858" txt_i="13121" txt_f="13124">3.9</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="29922" xml_f="29924" txt_i="13125" txt_f="13127">23</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="29988" xml_f="29990" txt_i="13128" txt_f="13130">19</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="30054" xml_f="30056" txt_i="13131" txt_f="13133">25</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="30120" xml_f="30123" txt_i="13134" txt_f="13137">4.4</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="30187" xml_f="30193" txt_i="13138" txt_f="13144">0.0007</offsets></td><td align="left" valign="bottom" rowspan="1" colspan="1"></td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="30326" xml_f="30351" txt_i="13146" txt_f="13171">A-S, day 7: MMP-8 (ng/ml)</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="30415" xml_f="30417" txt_i="13172" txt_f="13174">13</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="30481" xml_f="30484" txt_i="13175" txt_f="13178">1.9</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="30548" xml_f="30552" txt_i="13179" txt_f="13183">0.47</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="30616" xml_f="30619" txt_i="13184" txt_f="13187">5.1</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="30683" xml_f="30686" txt_i="13188" txt_f="13191">3.1</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="30750" xml_f="30753" txt_i="13192" txt_f="13195">3.1</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="30817" xml_f="30821" txt_i="13196" txt_f="13200">0.86</offsets></td><td align="left" valign="bottom" rowspan="1" colspan="1"></td><td align="left" valign="bottom" rowspan="1" colspan="1"></td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="31016" xml_f="31041" txt_i="13203" txt_f="13228">A-S, day 0: sRAGE (pg/ml)</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="31105" xml_f="31107" txt_i="13229" txt_f="13231">33</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="31171" xml_f="31174" txt_i="13232" txt_f="13235">363</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="31238" xml_f="31241" txt_i="13236" txt_f="13239">196</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="31305" xml_f="31310" txt_i="13240" txt_f="13245">1,209</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="31374" xml_f="31379" txt_i="13246" txt_f="13251">1,365</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="31443" xml_f="31448" txt_i="13252" txt_f="13257">2,390</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="31512" xml_f="31515" txt_i="13258" txt_f="13261">416</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="31579" xml_f="31589" txt_i="13262" txt_f="13269">&lt;0.0001</offsets></td><td align="left" valign="bottom" rowspan="1" colspan="1"></td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="31722" xml_f="31747" txt_i="13271" txt_f="13296">A-S, day 7: sRAGE (pg/ml)</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="31811" xml_f="31813" txt_i="13297" txt_f="13299">13</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="31877" xml_f="31879" txt_i="13300" txt_f="13302">77</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="31943" xml_f="31945" txt_i="13303" txt_f="13305">26</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="32009" xml_f="32012" txt_i="13306" txt_f="13309">127</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="32076" xml_f="32078" txt_i="13310" txt_f="13312">79</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="32142" xml_f="32144" txt_i="13313" txt_f="13315">53</offsets></td><td align="center" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="32208" xml_f="32210" txt_i="13316" txt_f="13318">15</offsets></td><td align="left" valign="bottom" rowspan="1" colspan="1"></td><td align="left" valign="bottom" rowspan="1" colspan="1"></td></tr></tbody></table><table-wrap-foot><p><italic><offsets xml_i="32388" xml_f="32660" txt_i="13321" txt_f="13593">Table of within-treatment group statistical differences, comparing days 0 to 7 levels of MMP-8, sRAGE, and ICAM-1. Day 0 compared to day 7 levels of PAI-1 and angiopoietin-2 did not differ. Methylprednisolone group (MPT), placebo group (P), all subjects (A-S), SD, and SEM</offsets></italic><offsets xml_i="32669" xml_f="32670" txt_i="13593" txt_f="13594">.</offsets></p></table-wrap-foot></table-wrap><fig id="F1" position="float"><label><offsets xml_i="32742" xml_f="32750" txt_i="13595" txt_f="13603">Figure 1</offsets></label><caption><p><bold><offsets xml_i="32776" xml_f="32858" txt_i="13603" txt_f="13685">Comparisons of biomarker levels between placebo and the MPT groups on days 0 and 7</offsets></bold><offsets xml_i="32865" xml_f="32990" txt_i="13685" txt_f="13810">. There are no differences between cytokine levels detected in MPT and control groups on day 0 or day 7. Two-tailed unpaired </offsets><italic><offsets xml_i="32998" xml_f="32999" txt_i="13810" txt_f="13811">t</offsets></italic><offsets xml_i="33008" xml_f="33012" txt_i="13811" txt_f="13815"> or </offsets><italic><offsets xml_i="33020" xml_f="33021" txt_i="13815" txt_f="13816">u</offsets></italic><offsets xml_i="33030" xml_f="33106" txt_i="13816" txt_f="13892"> test dependent were used dependent upon variances differences evaluated by </offsets><italic><offsets xml_i="33114" xml_f="33115" txt_i="13892" txt_f="13893">F</offsets></italic><offsets xml_i="33124" xml_f="33204" txt_i="13893" txt_f="13973"> test. On day 7, we observed a significant reduction in plasma levels of MMP-8 (</offsets><italic><offsets xml_i="33212" xml_f="33213" txt_i="13973" txt_f="13974">p</offsets></italic><offsets xml_i="33222" xml_f="33300" txt_i="13974" txt_f="14052"> = 0.0016) in the MPT and a significant increase in plasma levels of sICAM-1 (</offsets><italic><offsets xml_i="33308" xml_f="33309" txt_i="14052" txt_f="14053">p</offsets></italic><offsets xml_i="33318" xml_f="33464" txt_i="14053" txt_f="14199"> = 0.0005) in the placebo group (MPT group had no increase by day 7). Levels of sRAGE decreased significantly in both the MPT and placebo groups (</offsets><italic><offsets xml_i="33472" xml_f="33473" txt_i="14199" txt_f="14200">p</offsets></italic><offsets xml_i="33482" xml_f="33518" txt_i="14200" txt_f="14233"> &lt; 0.002) from day 0 to day 7. A </offsets><italic><offsets xml_i="33526" xml_f="33527" txt_i="14233" txt_f="14234">p</offsets></italic><offsets xml_i="33536" xml_f="33586" txt_i="14234" txt_f="14281">-value of &lt;0.05 was considered significant (*).</offsets></p></caption><graphic xlink:href="fped-04-00031-g001"></graphic></fig></sec><sec id="S3-2"><title><offsets xml_i="33685" xml_f="33737" txt_i="14283" txt_f="14335">Correlation between Biomarkers and Clinical Outcomes</offsets></title><p><offsets xml_i="33748" xml_f="33870" txt_i="14336" txt_f="14458">Pearson’s correlation tests analyzed associations between biomarker levels and the clinical outcomes reported previously (</offsets><xref rid="B6" ref-type="bibr"><offsets xml_i="33901" xml_f="33902" txt_i="14458" txt_f="14459">6</offsets></xref><offsets xml_i="33909" xml_f="34023" txt_i="14459" txt_f="14573">), including (1) P/F ratios on days 8 and 9, (2) mechanical ventilator plateau pressures on days 1 and 2, (3) PaCO</offsets><sub><offsets xml_i="34028" xml_f="34029" txt_i="14573" txt_f="14574">2</offsets></sub><offsets xml_i="34035" xml_f="34192" txt_i="14574" txt_f="14731"> values on days 2 and 3, (4) pH values on day 2, (5) need for racemic epinephrine following extubation, and (6) supplemental oxygen at PICU discharge (Table </offsets><xref ref-type="table" rid="T2"><offsets xml_i="34224" xml_f="34225" txt_i="14731" txt_f="14732">2</offsets></xref><offsets xml_i="34232" xml_f="34234" txt_i="14732" txt_f="14734">).</offsets></p><table-wrap id="T2" position="float"><label><offsets xml_i="34282" xml_f="34289" txt_i="14735" txt_f="14742">Table 2</offsets></label><caption><p><bold><offsets xml_i="34315" xml_f="34424" txt_i="14742" txt_f="14851">Pearson’s correlation table showing pairwise comparisons of clinical parameters of diseases and other factors</offsets></bold><offsets xml_i="34431" xml_f="34432" txt_i="14851" txt_f="14852">.</offsets></p></caption><table frame="hsides" rules="groups"><tbody><tr><td rowspan="1" colspan="1"><inline-graphic xlink:href="fped-04-00031-i001.jpg"></inline-graphic></td></tr></tbody></table><table-wrap-foot><p><italic><italic><offsets xml_i="34653" xml_f="34654" txt_i="14854" txt_f="14855">r</offsets></italic><offsets xml_i="34663" xml_f="34708" txt_i="14855" txt_f="14900"> is the Pearson’s correlation coefficient. A </offsets><italic><offsets xml_i="34716" xml_f="34717" txt_i="14900" txt_f="14901">p</offsets></italic><offsets xml_i="34726" xml_f="34814" txt_i="14901" txt_f="14986">-value of &lt;0.05 was considered significant and was derived from a paired, two-tailed </offsets><italic><offsets xml_i="34822" xml_f="34823" txt_i="14986" txt_f="14987">t</offsets></italic><offsets xml_i="34832" xml_f="34868" txt_i="14987" txt_f="15023">-test. MPT group (day 0: biomarkers </offsets><italic><offsets xml_i="34876" xml_f="34877" txt_i="15023" txt_f="15024">n</offsets></italic><offsets xml_i="34886" xml_f="34919" txt_i="15024" txt_f="15057"> = 14–15 and clinical parameters </offsets><italic><offsets xml_i="34927" xml_f="34928" txt_i="15057" txt_f="15058">n</offsets></italic><offsets xml_i="34937" xml_f="34965" txt_i="15058" txt_f="15086"> = 17 and day 7: biomarkers </offsets><italic><offsets xml_i="34973" xml_f="34974" txt_i="15086" txt_f="15087">n</offsets></italic><offsets xml_i="34983" xml_f="35012" txt_i="15087" txt_f="15116"> = 7 and clinical parameters </offsets><italic><offsets xml_i="35020" xml_f="35021" txt_i="15116" txt_f="15117">n</offsets></italic><offsets xml_i="35030" xml_f="35070" txt_i="15117" txt_f="15157"> = 8). Placebo group (day 0: biomarkers </offsets><italic><offsets xml_i="35078" xml_f="35079" txt_i="15157" txt_f="15158">n</offsets></italic><offsets xml_i="35088" xml_f="35121" txt_i="15158" txt_f="15191"> = 16–18 and clinical parameters </offsets><italic><offsets xml_i="35129" xml_f="35130" txt_i="15191" txt_f="15192">n</offsets></italic><offsets xml_i="35139" xml_f="35167" txt_i="15192" txt_f="15220"> = 18 and day 7: biomarkers </offsets><italic><offsets xml_i="35175" xml_f="35176" txt_i="15220" txt_f="15221">n</offsets></italic><offsets xml_i="35185" xml_f="35214" txt_i="15221" txt_f="15250"> = 7 and clinical parameters </offsets><italic><offsets xml_i="35222" xml_f="35223" txt_i="15250" txt_f="15251">n</offsets></italic><offsets xml_i="35232" xml_f="35237" txt_i="15251" txt_f="15256"> = 7)</offsets></italic><offsets xml_i="35246" xml_f="35247" txt_i="15256" txt_f="15257">.</offsets></p></table-wrap-foot></table-wrap><p><offsets xml_i="35285" xml_f="35346" txt_i="15258" txt_f="15319">Soluble receptor for activated glycation end product levels (</offsets><italic><offsets xml_i="35354" xml_f="35355" txt_i="15319" txt_f="15320">r</offsets></italic><offsets xml_i="35364" xml_f="35373" txt_i="15320" txt_f="15329"> = 0.93, </offsets><italic><offsets xml_i="35381" xml_f="35382" txt_i="15329" txt_f="15330">p</offsets></italic><offsets xml_i="35391" xml_f="35462" txt_i="15330" txt_f="15401"> = 0.024) on day 7 correlated positively with improved oxygenation (PaO</offsets><sub><offsets xml_i="35467" xml_f="35468" txt_i="15401" txt_f="15402">2</offsets></sub><offsets xml_i="35474" xml_f="35478" txt_i="15402" txt_f="15406">/FiO</offsets><sub><offsets xml_i="35483" xml_f="35484" txt_i="15406" txt_f="15407">2</offsets></sub><offsets xml_i="35490" xml_f="35532" txt_i="15407" txt_f="15449"> ratios) on day 8 in the MPT group (Table </offsets><xref ref-type="table" rid="T2"><offsets xml_i="35564" xml_f="35565" txt_i="15449" txt_f="15450">2</offsets></xref><offsets xml_i="35572" xml_f="35692" txt_i="15450" txt_f="15570">), but not in the placebo group. Plateau pressures on day 1 were positively correlated with sRAGE on day 0 in both MPT (</offsets><italic><offsets xml_i="35700" xml_f="35701" txt_i="15570" txt_f="15571">r</offsets></italic><offsets xml_i="35710" xml_f="35719" txt_i="15571" txt_f="15580"> = 0.66, </offsets><italic><offsets xml_i="35727" xml_f="35728" txt_i="15580" txt_f="15581">p</offsets></italic><offsets xml_i="35737" xml_f="35761" txt_i="15581" txt_f="15605"> = 0.007), and placebo (</offsets><italic><offsets xml_i="35769" xml_f="35770" txt_i="15605" txt_f="15606">r</offsets></italic><offsets xml_i="35779" xml_f="35788" txt_i="15606" txt_f="15615"> = 0.62, </offsets><italic><offsets xml_i="35796" xml_f="35797" txt_i="15615" txt_f="15616">p</offsets></italic><offsets xml_i="35806" xml_f="35923" txt_i="15616" txt_f="15733"> = 0.006) groups. Plateau pressure on day 1 was also positively correlated with Ang-2 on day 7 in the placebo group (</offsets><italic><offsets xml_i="35931" xml_f="35932" txt_i="15733" txt_f="15734">r</offsets></italic><offsets xml_i="35941" xml_f="35950" txt_i="15734" txt_f="15743"> = 0.86, </offsets><italic><offsets xml_i="35958" xml_f="35959" txt_i="15743" txt_f="15744">p</offsets></italic><offsets xml_i="35968" xml_f="36004" txt_i="15744" txt_f="15780"> = 0.013), but not in the MPT group.</offsets></p><p><offsets xml_i="36011" xml_f="36015" txt_i="15781" txt_f="15785">PaCO</offsets><sub><offsets xml_i="36020" xml_f="36021" txt_i="15785" txt_f="15786">2</offsets></sub><offsets xml_i="36027" xml_f="36169" txt_i="15786" txt_f="15928"> levels on days 2 and 3 did not correlate with any biomarker levels in either group. High pH on day 2 correlated with PAI-1 in the MPT group (</offsets><italic><offsets xml_i="36177" xml_f="36178" txt_i="15928" txt_f="15929">r</offsets></italic><offsets xml_i="36187" xml_f="36196" txt_i="15929" txt_f="15938"> = 0.67, </offsets><italic><offsets xml_i="36204" xml_f="36205" txt_i="15938" txt_f="15939">p</offsets></italic><offsets xml_i="36214" xml_f="36380" txt_i="15939" txt_f="16105"> = 0.009), but not in the placebo group. Racemic epinephrine therapy at extubation was positively correlated with MMP-8 in the placebo group on both day 0 and day 8 (</offsets><italic><offsets xml_i="36388" xml_f="36389" txt_i="16105" txt_f="16106">r</offsets></italic><offsets xml_i="36398" xml_f="36407" txt_i="16106" txt_f="16115"> = 0.55, </offsets><italic><offsets xml_i="36415" xml_f="36416" txt_i="16115" txt_f="16116">p</offsets></italic><offsets xml_i="36425" xml_f="36438" txt_i="16116" txt_f="16129"> = 0.021 and </offsets><italic><offsets xml_i="36446" xml_f="36447" txt_i="16129" txt_f="16130">r</offsets></italic><offsets xml_i="36456" xml_f="36465" txt_i="16130" txt_f="16139"> = 0.76, </offsets><italic><offsets xml_i="36473" xml_f="36474" txt_i="16139" txt_f="16140">p</offsets></italic><offsets xml_i="36483" xml_f="36533" txt_i="16140" txt_f="16190"> = 0.048, respectively), but not in the MPT group.</offsets></p><p><offsets xml_i="36540" xml_f="36641" txt_i="16191" txt_f="16292">Supplemental oxygen at ICU transfer was inversely correlated with sICAM-1 on day 7 in the MPT group (</offsets><italic><offsets xml_i="36649" xml_f="36650" txt_i="16292" txt_f="16293">r</offsets></italic><offsets xml_i="36659" xml_f="36669" txt_i="16293" txt_f="16303"> = −0.91, </offsets><italic><offsets xml_i="36677" xml_f="36678" txt_i="16303" txt_f="16304">p</offsets></italic><offsets xml_i="36687" xml_f="36770" txt_i="16304" txt_f="16387"> = 0.005), but in the placebo group, it positively correlated with PAI-1 on day 0 (</offsets><italic><offsets xml_i="36778" xml_f="36779" txt_i="16387" txt_f="16388">r</offsets></italic><offsets xml_i="36788" xml_f="36797" txt_i="16388" txt_f="16397"> = 0.75, </offsets><italic><offsets xml_i="36805" xml_f="36806" txt_i="16397" txt_f="16398">p</offsets></italic><offsets xml_i="36815" xml_f="36842" txt_i="16398" txt_f="16425"> = 0.000), MMP-8 on day 7 (</offsets><italic><offsets xml_i="36850" xml_f="36851" txt_i="16425" txt_f="16426">r</offsets></italic><offsets xml_i="36860" xml_f="36869" txt_i="16426" txt_f="16435"> = 0.85, </offsets><italic><offsets xml_i="36877" xml_f="36878" txt_i="16435" txt_f="16436">p</offsets></italic><offsets xml_i="36887" xml_f="36918" txt_i="16436" txt_f="16467"> = 0.016), and Ang-2 on day 7 (</offsets><italic><offsets xml_i="36926" xml_f="36927" txt_i="16467" txt_f="16468">r</offsets></italic><offsets xml_i="36936" xml_f="36945" txt_i="16468" txt_f="16477"> = 0.79, </offsets><italic><offsets xml_i="36953" xml_f="36954" txt_i="16477" txt_f="16478">p</offsets></italic><offsets xml_i="36963" xml_f="36973" txt_i="16478" txt_f="16488"> = 0.036).</offsets></p></sec></sec><sec sec-type="discussion" id="S4"><title><offsets xml_i="37031" xml_f="37041" txt_i="16491" txt_f="16501">Discussion</offsets></title><p><offsets xml_i="37052" xml_f="37138" txt_i="16502" txt_f="16588">A randomized controlled trial of low-dose MPT for children with early pediatric ARDS (</offsets><xref rid="B6" ref-type="bibr"><offsets xml_i="37169" xml_f="37170" txt_i="16588" txt_f="16589">6</offsets></xref><offsets xml_i="37177" xml_f="37559" txt_i="16589" txt_f="16968">) did not change mortality or morbidity (ventilator-free days at day 28) but altered the clinical parameters for oxygenation and ventilation. An observational study showed that 60% of pediatric patients received corticosteroids during the course of ARDS, and that exposure of corticosteroids for &gt;24 h was independently associated with longer duration of mechanical ventilation (</offsets><xref rid="B4" ref-type="bibr"><offsets xml_i="37590" xml_f="37591" txt_i="16968" txt_f="16969">4</offsets></xref><offsets xml_i="37598" xml_f="38064" txt_i="16969" txt_f="17435">). Those patients received corticosteroid with different regimens secondary to septic shock or other clinical indications. Thus, corticosteroid therapy for pediatric ARDS will remain controversial until larger controlled studies are performed. We propose that specific markers for endothelial or epithelial injury, coagulation and neutrophil activation, with known roles in the pathophysiology of ARDS, be selected as explanatory variables in future clinical trials.</offsets></p><p><offsets xml_i="38071" xml_f="38242" txt_i="17436" txt_f="17607">In our study, MMP-8 levels decreased in the MPT group, but did not change in the placebo group. Also MMP-8 levels at days 0 and 7 positively correlated with supplemental O</offsets><sub><offsets xml_i="38247" xml_f="38248" txt_i="17607" txt_f="17608">2</offsets></sub><offsets xml_i="38254" xml_f="38440" txt_i="17608" txt_f="17794"> at transfer from PICU in the placebo group. The role of MMP-8 is not only extracellular matrix turnover but also positive modulation of inflammation and other physiological activities (</offsets><xref rid="B9" ref-type="bibr"><offsets xml_i="38471" xml_f="38472" txt_i="17794" txt_f="17795">9</offsets></xref><offsets xml_i="38479" xml_f="38631" txt_i="17795" txt_f="17947">). In mice hyperoxia-induced acute lung injury model, MMP-8 was upregulated and seems to be produced in neutrophils, mesenchymal cell, and macrophages (</offsets><xref rid="B10" ref-type="bibr"><offsets xml_i="38663" xml_f="38665" txt_i="17947" txt_f="17949">10</offsets></xref><offsets xml_i="38672" xml_f="38905" txt_i="17949" txt_f="18182">). In ventilator-induced lung injury model, absence of MMP-8 by knockout mice or specific inhibition of MMP-8 were associated with improved gas exchange, decreased lung edema and permeability, and decreased histological lung injury (</offsets><xref rid="B11" ref-type="bibr"><offsets xml_i="38937" xml_f="38939" txt_i="18182" txt_f="18184">11</offsets></xref><offsets xml_i="38946" xml_f="39090" txt_i="18184" txt_f="18328">). Early elevations of MMP-8 in the bronchoalveolar lavage (BAL) fluid were associated with prolonged mechanical ventilation in pediatric ARDS (</offsets><xref rid="B12" ref-type="bibr"><offsets xml_i="39122" xml_f="39124" txt_i="18328" txt_f="18330">12</offsets></xref><offsets xml_i="39131" xml_f="39175" txt_i="18330" txt_f="18374">), greater acute lung injury with higher PaO</offsets><sub><offsets xml_i="39180" xml_f="39181" txt_i="18374" txt_f="18375">2</offsets></sub><offsets xml_i="39187" xml_f="39191" txt_i="18375" txt_f="18379">/FiO</offsets><sub><offsets xml_i="39196" xml_f="39197" txt_i="18379" txt_f="18380">2</offsets></sub><offsets xml_i="39203" xml_f="39230" txt_i="18380" txt_f="18407"> ratios in adult patients (</offsets><xref rid="B13" ref-type="bibr"><offsets xml_i="39262" xml_f="39264" txt_i="18407" txt_f="18409">13</offsets></xref><offsets xml_i="39271" xml_f="39318" txt_i="18409" txt_f="18456">), but did not predict their 90-day mortality (</offsets><xref rid="B14" ref-type="bibr"><offsets xml_i="39350" xml_f="39352" txt_i="18456" txt_f="18458">14</offsets></xref><offsets xml_i="39359" xml_f="39766" txt_i="18458" txt_f="18865">). Overall decreases in MMP-8 levels seem to be associated with the reduction in local and systemic inflammation. In this study, MMP-8 levels did not decrease and were positively correlated with IL-6 and IL-10 on days 0 and 7 in the placebo group, possibly due to sustained active inflammation even on day 7 in the placebo group. Therefore, we can generate a hypothesis that MPT decreased lung inflammation </offsets><italic><offsets xml_i="39774" xml_f="39777" txt_i="18865" txt_f="18868">via</offsets></italic><offsets xml_i="39786" xml_f="39978" txt_i="18868" txt_f="19060"> downregulation of MMP-8 in inflammatory cells, thus promoted early recovery from ARDS, and improved oxygenation in the recovery phase. This hypothesis needs to be validated in a future trial.</offsets></p><p><offsets xml_i="39985" xml_f="40217" txt_i="19061" txt_f="19293">During sepsis or ARDS, Ang-2 is upregulated in the endothelium and believed to antagonize Ang-1. Upregulated Ang-2 is associated with impaired endothelial barrier function and increased adhesion and migration of inflammatory cells (</offsets><xref rid="B15" ref-type="bibr"><offsets xml_i="40249" xml_f="40251" txt_i="19293" txt_f="19295">15</offsets></xref><offsets xml_i="40258" xml_f="40354" txt_i="19295" txt_f="19391">). Clinical studies in adults demonstrated higher plasma Ang-2 concentrations in ARDS patients (</offsets><xref rid="B16" ref-type="bibr"><offsets xml_i="40386" xml_f="40388" txt_i="19391" txt_f="19393">16</offsets></xref><offsets xml_i="40395" xml_f="40446" txt_i="19393" txt_f="19444">), also associated with later development of ARDS (</offsets><xref rid="B17" ref-type="bibr"><offsets xml_i="40478" xml_f="40480" txt_i="19444" txt_f="19446">17</offsets></xref><offsets xml_i="40487" xml_f="40528" txt_i="19446" txt_f="19487">), and ARDS mortality in adult patients (</offsets><xref rid="B18" ref-type="bibr"><offsets xml_i="40560" xml_f="40562" txt_i="19487" txt_f="19489">18</offsets></xref><offsets xml_i="40569" xml_f="40571" txt_i="19489" txt_f="19491">, </offsets><xref rid="B19" ref-type="bibr"><offsets xml_i="40603" xml_f="40605" txt_i="19491" txt_f="19493">19</offsets></xref><offsets xml_i="40612" xml_f="40741" txt_i="19493" txt_f="19622">). Children with severe sepsis or septic shock have higher Ang-2 levels or Ang-2/Ang-1 ratios as compared to patients with SIRS (</offsets><xref rid="B20" ref-type="bibr"><offsets xml_i="40773" xml_f="40775" txt_i="19622" txt_f="19624">20</offsets></xref><offsets xml_i="40782" xml_f="40896" txt_i="19624" txt_f="19738">). In this study, Ang-2 levels on day 7 correlated with plateau pressures on day 1 and the need for supplemental O</offsets><sub><offsets xml_i="40901" xml_f="40902" txt_i="19738" txt_f="19739">2</offsets></sub><offsets xml_i="40908" xml_f="41254" txt_i="19739" txt_f="20085"> at ICU discharge in the placebo group. This may indicate that acute lung injury on day 1 correlated with endothelial injury on day 7 and endothelial injury on day 7 correlated with oxygenation at ICU discharge. In the MPT group, Ang-2 levels on day 7 negatively correlated with IL-1RA. This may indicate that MPT may decrease endothelial injury </offsets><italic><offsets xml_i="41262" xml_f="41265" txt_i="20085" txt_f="20088">via</offsets></italic><offsets xml_i="41274" xml_f="41323" txt_i="20088" txt_f="20137"> induction of anti-inflammatory cytokine, IL-1RA.</offsets></p><p><offsets xml_i="41330" xml_f="41484" txt_i="20138" txt_f="20292">Soluble intercellular adhesion molecule-1 is an adhesion molecule expressed in the membrane of leukocytes, vascular endothelium, and alveolar epithelium (</offsets><xref rid="B21" ref-type="bibr"><offsets xml_i="41516" xml_f="41518" txt_i="20292" txt_f="20294">21</offsets></xref><offsets xml_i="41525" xml_f="41660" txt_i="20294" txt_f="20429">). It is involved in neutrophil recruitment into the lung. In adults, plasma sICAM-1 levels appear to correlate with ARDS development (</offsets><xref rid="B22" ref-type="bibr"><offsets xml_i="41692" xml_f="41694" txt_i="20429" txt_f="20431">22</offsets></xref><offsets xml_i="41701" xml_f="41703" txt_i="20431" txt_f="20433">, </offsets><xref rid="B23" ref-type="bibr"><offsets xml_i="41735" xml_f="41737" txt_i="20433" txt_f="20435">23</offsets></xref><offsets xml_i="41744" xml_f="41766" txt_i="20435" txt_f="20457">) and ARDS mortality (</offsets><xref rid="B22" ref-type="bibr"><offsets xml_i="41798" xml_f="41800" txt_i="20457" txt_f="20459">22</offsets></xref><offsets xml_i="41807" xml_f="41809" txt_i="20459" txt_f="20461">, </offsets><xref rid="B24" ref-type="bibr"><offsets xml_i="41841" xml_f="41843" txt_i="20461" txt_f="20463">24</offsets></xref><offsets xml_i="41850" xml_f="41852" txt_i="20463" txt_f="20465">, </offsets><xref rid="B25" ref-type="bibr"><offsets xml_i="41884" xml_f="41886" txt_i="20465" txt_f="20467">25</offsets></xref><offsets xml_i="41893" xml_f="42032" txt_i="20467" txt_f="20606">). In pediatric ARDS, early elevation of sICAM-1 was associated with prolonged duration of mechanical ventilation and increased mortality (</offsets><xref rid="B26" ref-type="bibr"><offsets xml_i="42064" xml_f="42066" txt_i="20606" txt_f="20608">26</offsets></xref><offsets xml_i="42073" xml_f="42075" txt_i="20608" txt_f="20610">, </offsets><xref rid="B27" ref-type="bibr"><offsets xml_i="42107" xml_f="42109" txt_i="20610" txt_f="20612">27</offsets></xref><offsets xml_i="42116" xml_f="42276" txt_i="20612" txt_f="20772">). In this study, sICAM-1 levels increased from day 0 to 7 in the placebo group, whereas in the MPT group sICAM-1 levels on day 7 were positive predictors for O</offsets><sub><offsets xml_i="42281" xml_f="42282" txt_i="20772" txt_f="20773">2</offsets></sub><offsets xml_i="42288" xml_f="42993" txt_i="20773" txt_f="21478"> supplement at transfer. This indicates that MPT may prevent endothelial injury, decrease permeability, and improve pulmonary edema leading to improved oxygenation. sICAM-1 levels correlated with Ang-2 levels on days 0 and 7, indicating similar roles as endothelial injury biomarkers. Interestingly, both sICAM-1 and Ang-2 levels in the placebo group had positive correlation with many cytokines on day 7. However, in the MPT group, Ang-2 and sICAM-1 on day 7 did not correlate with these cytokines. These findings may indicate that the endothelial injury underlying pediatric ARDS may continue until later phases of ARDS, dependent upon the degree of the inflammation, if not treated with corticosteroid.</offsets></p><p><offsets xml_i="43000" xml_f="43363" txt_i="21479" txt_f="21842">Soluble receptor for activated glycation end products, the secreted forms of the epithelial RAGE membrane receptors, are multiligand-binding receptors that can bind advanced glycation end products, amyloid beta-peptide, S100 proteins, and high-mobility group box-1. It results in activation of the pro-inflammatory transcription factor nuclear factor-kB (NF-kB) (</offsets><xref rid="B28" ref-type="bibr"><offsets xml_i="43395" xml_f="43397" txt_i="21842" txt_f="21844">28</offsets></xref><offsets xml_i="43404" xml_f="43482" txt_i="21844" txt_f="21922">). sRAGE levels in plasma and BAL were elevated in rat models of lung injury (</offsets><xref rid="B29" ref-type="bibr"><offsets xml_i="43514" xml_f="43516" txt_i="21922" txt_f="21924">29</offsets></xref><offsets xml_i="43523" xml_f="43659" txt_i="21924" txt_f="22060">). In adult ARDS studies, its results are controversial. In adult ARDS, sRAGE level was associated with ARDS development and mortality (</offsets><xref rid="B30" ref-type="bibr"><offsets xml_i="43691" xml_f="43693" txt_i="22060" txt_f="22062">30</offsets></xref><offsets xml_i="43700" xml_f="43702" txt_i="22062" txt_f="22064">, </offsets><xref rid="B31" ref-type="bibr"><offsets xml_i="43734" xml_f="43736" txt_i="22064" txt_f="22066">31</offsets></xref><offsets xml_i="43743" xml_f="43838" txt_i="22066" txt_f="22161">). However, in other studies, sRAGE did not show any association with the development of ARDS (</offsets><xref rid="B17" ref-type="bibr"><offsets xml_i="43870" xml_f="43872" txt_i="22161" txt_f="22163">17</offsets></xref><offsets xml_i="43879" xml_f="43881" txt_i="22163" txt_f="22165">, </offsets><xref rid="B32" ref-type="bibr"><offsets xml_i="43913" xml_f="43915" txt_i="22165" txt_f="22167">32</offsets></xref><offsets xml_i="43922" xml_f="43924" txt_i="22167" txt_f="22169">, </offsets><xref rid="B33" ref-type="bibr"><offsets xml_i="43956" xml_f="43958" txt_i="22169" txt_f="22171">33</offsets></xref><offsets xml_i="43965" xml_f="44063" txt_i="22171" txt_f="22269">). Recent study demonstrated that serum sRAGE was elevated in children with severe bronchiolitis (</offsets><xref rid="B34" ref-type="bibr"><offsets xml_i="44095" xml_f="44097" txt_i="22269" txt_f="22271">34</offsets></xref><offsets xml_i="44104" xml_f="44831" txt_i="22271" txt_f="22998">); however, there are no published data in pediatric ARDS. In this study, sRAGE levels decreased in all subjects, MPT, and the placebo groups from days 0 to 7. Furthermore, sRAGE levels on day 0 are predictors of higher plateau pressure on day 1 in both the groups. This indicates that higher plateau pressure correlated with more epithelial injury in early ARDS. However, by day 7, sRAGE levels decreased in both the MPT and placebo groups. Does this indicate that epithelial injury is more likely in the early stages of ARDS compared to the later stage? sRAGE levels on day 0 positively correlated with IL-6 levels in both the MPT and placebo groups, and this could be a manifestation of the pro-inflammatory effect of sRAGE.</offsets></p><p><offsets xml_i="44838" xml_f="45044" txt_i="22999" txt_f="23205">Plasminogen activator inhibitor-1 is an anti-fibrinolytic agent. During ARDS, deposition of fibrin in the alveolar space is observed with disruption of the lung endothelial and alveolar epithelial barrier (</offsets><xref rid="B35" ref-type="bibr"><offsets xml_i="45076" xml_f="45078" txt_i="23205" txt_f="23207">35</offsets></xref><offsets xml_i="45085" xml_f="45220" txt_i="23207" txt_f="23342">). Elevation of PAI-1 activity in plasma and air spaces associated with a decrease in alveolar fibrinolysis is observed in early ARDS (</offsets><xref rid="B36" ref-type="bibr"><offsets xml_i="45252" xml_f="45254" txt_i="23342" txt_f="23344">36</offsets></xref><offsets xml_i="45261" xml_f="45397" txt_i="23344" txt_f="23480">). In a secondary analysis from adult ARDS patients, an elevated plasma PAI-1 level was significantly associated with poor oxygenation (</offsets><xref rid="B37" ref-type="bibr"><offsets xml_i="45429" xml_f="45431" txt_i="23480" txt_f="23482">37</offsets></xref><offsets xml_i="45438" xml_f="45517" txt_i="23482" txt_f="23561">). Elevated plasma PAI-1 was also associated with mortality in pediatric ARDS (</offsets><xref rid="B38" ref-type="bibr"><offsets xml_i="45549" xml_f="45551" txt_i="23561" txt_f="23563">38</offsets></xref><offsets xml_i="45558" xml_f="45931" txt_i="23563" txt_f="23936">). In this study, PAI-1 levels on day 0 correlated positively with high pH in the MPT group and were predictors of high pH on day 2 in our linear regression model. On day 0, PAI-1 level correlated positively with many cytokines and chemokines. This indicates that increased severity of inflammation may be associated with the deposition of fibrin in earlier stages of ARDS.</offsets></p><p><offsets xml_i="45938" xml_f="46109" txt_i="23937" txt_f="24108">In adult ARDS, the same MPT protocol was associated with decreases in plasma IL-6 and proadrenomedullin levels and increases in protein C levels, compared to the placebo (</offsets><xref rid="B39" ref-type="bibr"><offsets xml_i="46141" xml_f="46143" txt_i="24108" txt_f="24110">39</offsets></xref><offsets xml_i="46150" xml_f="46223" txt_i="24110" txt_f="24183">). As previously reported, MPT decreased IL-6 in pediatric ARDS as well (</offsets><xref rid="B8" ref-type="bibr"><offsets xml_i="46254" xml_f="46255" txt_i="24183" txt_f="24184">8</offsets></xref><offsets xml_i="46262" xml_f="46658" txt_i="24184" txt_f="24580">). Considering the biomarker changes in this study, we propose that corticosteroids may attenuate inflammation, promote early recovery from the epithelial injury, and prevent sustained endothelial damage, leading to earlier improvement in pulmonary edema and oxygenation seen as clinical outcomes. This hypothesis should be tested in larger clinical trials of MPT in pediatric ARDS in the future.</offsets></p><p><offsets xml_i="46665" xml_f="46995" txt_i="24581" txt_f="24911">This is the first study to measure plasma biomarkers for endothelial and epithelial injury at the different time points of pediatric ARDS. However, proteomic analysis methods have further advanced, and now it is technically possible to measure 1,310 protein levels simultaneously and precisely from just 150 μl of plasma samples (</offsets><xref rid="B40" ref-type="bibr"><offsets xml_i="47027" xml_f="47029" txt_i="24911" txt_f="24913">40</offsets></xref><offsets xml_i="47036" xml_f="47038" txt_i="24913" txt_f="24915">, </offsets><xref rid="B41" ref-type="bibr"><offsets xml_i="47070" xml_f="47072" txt_i="24915" txt_f="24917">41</offsets></xref><offsets xml_i="47079" xml_f="47206" txt_i="24917" txt_f="25044">). Combinations of these biomarkers could discover novel therapeutic options and predictors of clinical outcomes in the future.</offsets></p><p><offsets xml_i="47213" xml_f="47862" txt_i="25045" txt_f="25694">Limitations of this study include a relatively small number of samples; therefore, our results need to be validated in larger clinical trials. Our clinical trial was designed to demonstrate the feasibility of the MPT protocol in pediatric early ARDS. Our biomarker analysis was not the main purpose of the study and we could not conduct functional analyses. Also, we only obtained clinical samples on days 0 and 7, whereas the timing for peak levels of these biomarkers may be different. Finally, we did not conduct BAL fluid collection or lung biopsy, so our results may not represent local pulmonary the changes but may represent systemic changes.</offsets></p></sec><sec id="S5"><title><offsets xml_i="47892" xml_f="47902" txt_i="25696" txt_f="25706">Conclusion</offsets></title><p><offsets xml_i="47913" xml_f="48477" txt_i="25707" txt_f="26271">In this study, we demonstrated changes in selected biomarkers of ARDS between the placebo and MPT groups that were correlated with clinical endpoints. We cannot provide meaningful conclusions due to small sample size. However, we can generate a hypothesis that the anti-inflammatory effects of MPT may allow faster epithelial recovery manifested by decreases in sRAGE levels, thus avoiding sustained endothelial injury associated with elevated sICAM-1 levels in the placebo group. Future controlled studies with larger sample sizes should validate this hypothesis.</offsets></p></sec><sec id="S6"><title><offsets xml_i="48507" xml_f="48527" txt_i="26273" txt_f="26293">Author Contributions</offsets></title><p><offsets xml_i="48538" xml_f="48793" txt_i="26294" txt_f="26549">DK, SC, and KA: conception and design of study. DK: acquisition of data. DK, JS, CR, GM, AS, SC, and KA: analysis and interpretation of data and drafting and critically revising the manuscript. All the authors approved the final version of the manuscript.</offsets></p></sec><sec id="S7"><title><offsets xml_i="48823" xml_f="48853" txt_i="26551" txt_f="26581">Conflict of Interest Statement</offsets></title><p><offsets xml_i="48864" xml_f="49036" txt_i="26582" txt_f="26754">The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</offsets></p></sec></body><back><sec id="S8"><title>Funding</title><p>This study was supported by National Institute of Health (7KO8HL118118-03, R01AI090059, R01ES015050, P42ES013648) and Le Bonheur Foundation grant (641003). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></sec><sec id="S9"><title>Abbreviations</title><p>Ang-2, angiopoietin-2; ARDS, acute respiratory distress syndrome; ICU, intensive care unit; MMP-8, matrix metalloproteinase-8; MPT, methylprednisolone; PAI-1, plasminogen activator inhibitor-1; PICU, pediatric intensive care unit; sICAM-1, soluble intercellular adhesion molecule-1; SIRS, systemic inflammatory response syndrome; sRAGE, soluble receptor for activated glycation end products.</p></sec><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ware</surname><given-names>LB</given-names></name><name><surname>Matthay</surname><given-names>MA</given-names></name></person-group>
<article-title>The acute respiratory distress syndrome</article-title>. <source>N Engl J Med</source> (<year>2000</year>) <volume>342</volume>(<issue>18</issue>):<fpage>1334</fpage>–<lpage>49</lpage>.<pub-id pub-id-type="doi">10.1056/NEJM200005043421806</pub-id><pub-id pub-id-type="pmid">10793167</pub-id></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hough</surname><given-names>CL</given-names></name></person-group>. <article-title>Steroids for acute respiratory distress syndrome?</article-title>
<source>Clin Chest Med</source> (<year>2014</year>) <volume>35</volume>(<issue>4</issue>):<fpage>781</fpage>–<lpage>95</lpage>.<pub-id pub-id-type="doi">10.1016/j.ccm.2014.08.014</pub-id><pub-id pub-id-type="pmid">25453425</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meduri</surname><given-names>GU</given-names></name><name><surname>Golden</surname><given-names>E</given-names></name><name><surname>Freire</surname><given-names>AX</given-names></name><name><surname>Taylor</surname><given-names>E</given-names></name><name><surname>Zaman</surname><given-names>M</given-names></name><name><surname>Carson</surname><given-names>SJ</given-names></name><etal></etal></person-group>
<article-title>Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial</article-title>. <source>Chest</source> (<year>2007</year>) <volume>131</volume>(<issue>4</issue>):<fpage>954</fpage>–<lpage>63</lpage>.<pub-id pub-id-type="doi">10.1378/chest.06-2100</pub-id><pub-id pub-id-type="pmid">17426195</pub-id></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yehya</surname><given-names>N</given-names></name><name><surname>Servaes</surname><given-names>S</given-names></name><name><surname>Thomas</surname><given-names>NJ</given-names></name><name><surname>Nadkarni</surname><given-names>VM</given-names></name><name><surname>Srinivasan</surname><given-names>V</given-names></name></person-group>
<article-title>Corticosteroid exposure in pediatric acute respiratory distress syndrome</article-title>. <source>Intensive Care Med</source> (<year>2015</year>) <volume>41</volume>(<issue>9</issue>):<fpage>1658</fpage>–<lpage>66</lpage>.<pub-id pub-id-type="doi">10.1007/s00134-015-3953-4</pub-id><pub-id pub-id-type="pmid">26160728</pub-id></mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwingshackl</surname><given-names>A</given-names></name><name><surname>Meduri</surname><given-names>GU</given-names></name><name><surname>Kimura</surname><given-names>D</given-names></name><name><surname>Cormier</surname><given-names>SA</given-names></name><name><surname>Anand</surname><given-names>KJ</given-names></name></person-group>
<article-title>Corticosteroids in pediatric ARDS: all cards on the table</article-title>. <source>Intensive Care Med</source> (<year>2015</year>) <volume>41</volume>(<issue>11</issue>):<fpage>2036</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1007/s00134-015-4027-3</pub-id><pub-id pub-id-type="pmid">26359160</pub-id></mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drago</surname><given-names>BB</given-names></name><name><surname>Kimura</surname><given-names>D</given-names></name><name><surname>Rovnaghi</surname><given-names>CR</given-names></name><name><surname>Schwingshackl</surname><given-names>A</given-names></name><name><surname>Rayburn</surname><given-names>M</given-names></name><name><surname>Meduri</surname><given-names>GU</given-names></name><etal></etal></person-group>
<article-title>Double-blind, placebo-controlled pilot randomized trial of methylprednisolone infusion in pediatric acute respiratory distress syndrome</article-title>. <source>Pediatr Crit Care Med</source> (<year>2015</year>) <volume>16</volume>(<issue>3</issue>):<fpage>e74</fpage>–<lpage>81</lpage>.<pub-id pub-id-type="doi">10.1097/PCC.0000000000000349</pub-id><pub-id pub-id-type="pmid">25634565</pub-id></mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meduri</surname><given-names>GU</given-names></name><name><surname>Marik</surname><given-names>PE</given-names></name><name><surname>Chrousos</surname><given-names>GP</given-names></name><name><surname>Pastores</surname><given-names>SM</given-names></name><name><surname>Arlt</surname><given-names>W</given-names></name><name><surname>Beishuizen</surname><given-names>A</given-names></name><etal></etal></person-group>
<article-title>Steroid treatment in ARDS: a critical appraisal of the ARDS network trial and the recent literature</article-title>. <source>Intensive Care Med</source> (<year>2008</year>) <volume>34</volume>(<issue>1</issue>):<fpage>61</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1007/s00134-007-0933-3</pub-id><pub-id pub-id-type="pmid">18000649</pub-id></mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwingshackl</surname><given-names>A</given-names></name><name><surname>Kimura</surname><given-names>D</given-names></name><name><surname>Rovnaghi</surname><given-names>CR</given-names></name><name><surname>Saravia</surname><given-names>SJ</given-names></name><name><surname>Cormier</surname><given-names>AS</given-names></name><name><surname>Teng</surname><given-names>B</given-names></name><etal></etal></person-group>
<article-title>Regulation of inflammatory biomarkers by intravenous methylprednisolone in pediatric ARDS patients: results from a double-blind, placebo-controlled randomized pilot trial</article-title>. <source>Cytokine</source> (<year>2016</year>) <volume>77</volume>(<issue>1</issue>):<fpage>63</fpage>–<lpage>71</lpage>.<pub-id pub-id-type="doi">10.1016/j.cyto.2015.10.007</pub-id><pub-id pub-id-type="pmid">26545141</pub-id></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dejonckheere</surname><given-names>E</given-names></name><name><surname>Vandenbroucke</surname><given-names>RE</given-names></name><name><surname>Libert</surname><given-names>C</given-names></name></person-group>. <article-title>Matrix metalloproteinase8 has a central role in inflammatory disorders and cancer progression</article-title>. <source>Cytokine Growth Factor Rev</source> (<year>2011</year>) <volume>22</volume>(<issue>2</issue>):<fpage>73</fpage>–<lpage>81</lpage>.<pub-id pub-id-type="doi">10.1016/j.cytogfr.2011.02.002</pub-id><pub-id pub-id-type="pmid">21388856</pub-id></mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cederqvist</surname><given-names>K</given-names></name><name><surname>Janer</surname><given-names>J</given-names></name><name><surname>Tervahartiala</surname><given-names>T</given-names></name><name><surname>Sorsa</surname><given-names>T</given-names></name><name><surname>Haglund</surname><given-names>C</given-names></name><name><surname>Salmenkivi</surname><given-names>K</given-names></name><etal></etal></person-group>
<article-title>Up-regulation of trypsin and mesenchymal MMP-8 during development of hyperoxic lung injury in the rat</article-title>. <source>Pediatr Res</source> (<year>2006</year>) <volume>60</volume>(<issue>4</issue>):<fpage>395</fpage>–<lpage>400</lpage>.<pub-id pub-id-type="doi">10.1203/01.pdr.0000238342.16081.f9</pub-id><pub-id pub-id-type="pmid">16940237</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albaiceta</surname><given-names>GM</given-names></name><name><surname>Gutierrez-Fernandez</surname><given-names>A</given-names></name><name><surname>Garcia-Prieto</surname><given-names>E</given-names></name><name><surname>Puente</surname><given-names>XS</given-names></name><name><surname>Parra</surname><given-names>D</given-names></name><name><surname>Astudillo</surname><given-names>A</given-names></name><etal></etal></person-group>
<article-title>Absence or inhibition of matrix metalloproteinase-8 decreases ventilator-induced lung injury</article-title>. <source>Am J Respir Cell Mol Biol</source> (<year>2010</year>) <volume>43</volume>(<issue>5</issue>):<fpage>555</fpage>–<lpage>63</lpage>.<pub-id pub-id-type="doi">10.1165/rcmb.2009-0034OC</pub-id><pub-id pub-id-type="pmid">19995943</pub-id></mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kong</surname><given-names>MY</given-names></name><name><surname>Gaggar</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Winkler</surname><given-names>M</given-names></name><name><surname>Blalock</surname><given-names>JE</given-names></name><name><surname>Clancy</surname><given-names>JP</given-names></name></person-group>. <article-title>Matrix metalloproteinase activity in pediatric acute lung injury</article-title>. <source>Int J Med Sci</source> (<year>2009</year>) <volume>6</volume>(<issue>1</issue>):<fpage>9</fpage>–<lpage>17</lpage>.<pub-id pub-id-type="doi">10.7150/ijms.6.9</pub-id><pub-id pub-id-type="pmid">19159011</pub-id></mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fligiel</surname><given-names>SE</given-names></name><name><surname>Standiford</surname><given-names>T</given-names></name><name><surname>Fligiel</surname><given-names>HM</given-names></name><name><surname>Tashkin</surname><given-names>D</given-names></name><name><surname>Strieter</surname><given-names>RM</given-names></name><name><surname>Warner</surname><given-names>RL</given-names></name><etal></etal></person-group>
<article-title>Matrix metalloproteinases and matrix metalloproteinase inhibitors in acute lung injury</article-title>. <source>Hum Pathol</source> (<year>2006</year>) <volume>37</volume>(<issue>4</issue>):<fpage>422</fpage>–<lpage>30</lpage>.<pub-id pub-id-type="doi">10.1016/j.humpath.2005.11.023</pub-id><pub-id pub-id-type="pmid">16564916</pub-id></mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hastbacka</surname><given-names>J</given-names></name><name><surname>Linko</surname><given-names>R</given-names></name><name><surname>Tervahartiala</surname><given-names>T</given-names></name><name><surname>Varpula</surname><given-names>T</given-names></name><name><surname>Hovilehto</surname><given-names>S</given-names></name><name><surname>Parviainen</surname><given-names>I</given-names></name><etal></etal></person-group>
<article-title>Serum MMP-8 and TIMP-1 in critically ill patients with acute respiratory failure: TIMP-1 is associated with increased 90-day mortality</article-title>. <source>Anesth Analg</source> (<year>2014</year>) <volume>118</volume>(<issue>4</issue>):<fpage>790</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1213/ANE.0000000000000120</pub-id><pub-id pub-id-type="pmid">24651234</pub-id></mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parikh</surname><given-names>SM</given-names></name></person-group>. <article-title>Dysregulation of the angiopoietin-Tie-2 axis in sepsis and ARDS</article-title>. <source>Virulence</source> (<year>2013</year>) <volume>4</volume>(<issue>6</issue>):<fpage>517</fpage>–<lpage>24</lpage>.<pub-id pub-id-type="doi">10.4161/viru.24906</pub-id><pub-id pub-id-type="pmid">23652985</pub-id></mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Heijden</surname><given-names>M</given-names></name><name><surname>van Nieuw Amerongen</surname><given-names>GP</given-names></name><name><surname>Koolwijk</surname><given-names>P</given-names></name><name><surname>van Hinsbergh</surname><given-names>VW</given-names></name><name><surname>Groeneveld</surname><given-names>AB</given-names></name></person-group>. <article-title>Angiopoietin-2, permeability oedema, occurrence and severity of ALI/ARDS in septic and non-septic critically ill patients</article-title>. <source>Thorax</source> (<year>2008</year>) <volume>63</volume>(<issue>10</issue>):<fpage>903</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1136/thx.2007.087387</pub-id><pub-id pub-id-type="pmid">18559364</pub-id></mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agrawal</surname><given-names>A</given-names></name><name><surname>Matthay</surname><given-names>MA</given-names></name><name><surname>Kangelaris</surname><given-names>KN</given-names></name><name><surname>Stein</surname><given-names>J</given-names></name><name><surname>Chu</surname><given-names>JC</given-names></name><name><surname>Imp</surname><given-names>BM</given-names></name><etal></etal></person-group>
<article-title>Plasma angiopoietin-2 predicts the onset of acute lung injury in critically ill patients</article-title>. <source>Am J Respir Crit Care Med</source> (<year>2013</year><volume>187</volume>(<issue>7</issue>):<fpage>736</fpage>–<lpage>42</lpage>.<pub-id pub-id-type="doi">10.1164/rccm.201208-1460OC</pub-id><pub-id pub-id-type="pmid">23328529</pub-id></mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gallagher</surname><given-names>DC</given-names></name><name><surname>Parikh</surname><given-names>SM</given-names></name><name><surname>Balonov</surname><given-names>K</given-names></name><name><surname>Miller</surname><given-names>A</given-names></name><name><surname>Gautam</surname><given-names>S</given-names></name><name><surname>Talmor</surname><given-names>D</given-names></name><etal></etal></person-group>
<article-title>Circulating angiopoietin 2 correlates with mortality in a surgical population with acute lung injury/adult respiratory distress syndrome</article-title>. <source>Shock</source> (<year>2008</year>) <volume>29</volume>(<issue>6</issue>):<fpage>656</fpage>–<lpage>61</lpage>.<pub-id pub-id-type="doi">10.1097/SHK.0b013e31815dd92f</pub-id><pub-id pub-id-type="pmid">18091573</pub-id></mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calfee</surname><given-names>CS</given-names></name><name><surname>Gallagher</surname><given-names>D</given-names></name><name><surname>Abbott</surname><given-names>J</given-names></name><name><surname>Thompson</surname><given-names>BT</given-names></name><name><surname>Matthay</surname><given-names>MA</given-names></name><name><surname>Network</surname><given-names>NA</given-names></name></person-group>. <article-title>Plasma angiopoietin-2 in clinical acute lung injury: prognostic and pathogenetic significance</article-title>. <source>Crit Care Med</source> (<year>2012</year>) <volume>40</volume>(<issue>6</issue>):<fpage>1731</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1097/CCM.0b013e3182451c87</pub-id><pub-id pub-id-type="pmid">22610178</pub-id></mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giuliano</surname><given-names>JS</given-names><suffix>Jr</suffix></name><name><surname>Lahni</surname><given-names>PM</given-names></name><name><surname>Harmon</surname><given-names>K</given-names></name><name><surname>Wong</surname><given-names>HR</given-names></name><name><surname>Doughty</surname><given-names>LA</given-names></name><name><surname>Carcillo</surname><given-names>JA</given-names></name><etal></etal></person-group>
<article-title>Admission angiopoietin levels in children with septic shock</article-title>. <source>Shock</source> (<year>2007</year>) <volume>28</volume>(<issue>6</issue>):<fpage>650</fpage>–<lpage>4</lpage>.<pub-id pub-id-type="doi">10.1097/shk.0b013e318123867b</pub-id><pub-id pub-id-type="pmid">18092380</pub-id></mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van de Stolpe</surname><given-names>A</given-names></name><name><surname>van der Saag</surname><given-names>PT</given-names></name></person-group>. <article-title>Intercellular adhesion molecule-1</article-title>. <source>J Mol Med</source> (<year>1996</year>) <volume>74</volume>(<issue>1</issue>):<fpage>13</fpage>–<lpage>33</lpage>.<pub-id pub-id-type="doi">10.1007/BF00202069</pub-id><pub-id pub-id-type="pmid">8834767</pub-id></mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calfee</surname><given-names>CS</given-names></name><name><surname>Eisner</surname><given-names>MD</given-names></name><name><surname>Parsons</surname><given-names>PE</given-names></name><name><surname>Thompson</surname><given-names>BT</given-names></name><name><surname>Conner</surname><given-names>ER</given-names><suffix>Jr</suffix></name><name><surname>Matthay</surname><given-names>MA</given-names></name><etal></etal></person-group>
<article-title>Soluble intercellular adhesion molecule-1 and clinical outcomes in patients with acute lung injury</article-title>. <source>Intensive Care Med</source> (<year>2009</year>) <volume>35</volume>(<issue>2</issue>):<fpage>248</fpage>–<lpage>57</lpage>.<pub-id pub-id-type="doi">10.1007/s00134-008-1235-0</pub-id><pub-id pub-id-type="pmid">18670758</pub-id></mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cepkova</surname><given-names>M</given-names></name><name><surname>Brady</surname><given-names>S</given-names></name><name><surname>Sapru</surname><given-names>A</given-names></name><name><surname>Matthay</surname><given-names>MA</given-names></name><name><surname>Church</surname><given-names>G</given-names></name></person-group>. <article-title>Biological markers of lung injury before and after the institution of positive pressure ventilation in patients with acute lung injury</article-title>. <source>Crit Care</source> (<year>2006</year>) <volume>10</volume>(<issue>5</issue>):<fpage>R126</fpage>.<pub-id pub-id-type="doi">10.1186/cc4842</pub-id><pub-id pub-id-type="pmid">16956410</pub-id></mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McClintock</surname><given-names>D</given-names></name><name><surname>Zhuo</surname><given-names>H</given-names></name><name><surname>Wickersham</surname><given-names>N</given-names></name><name><surname>Matthay</surname><given-names>MA</given-names></name><name><surname>Ware</surname><given-names>LB</given-names></name></person-group>. <article-title>Biomarkers of inflammation, coagulation and fibrinolysis predict mortality in acute lung injury</article-title>. <source>Crit Care</source> (<year>2008</year>) <volume>12</volume>(<issue>2</issue>):<fpage>R41</fpage>.<pub-id pub-id-type="doi">10.1186/cc6846</pub-id><pub-id pub-id-type="pmid">18358078</pub-id></mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calfee</surname><given-names>CS</given-names></name><name><surname>Ware</surname><given-names>LB</given-names></name><name><surname>Glidden</surname><given-names>DV</given-names></name><name><surname>Eisner</surname><given-names>MD</given-names></name><name><surname>Parsons</surname><given-names>PE</given-names></name><name><surname>Thompson</surname><given-names>BT</given-names></name><etal></etal></person-group>
<article-title>Use of risk reclassification with multiple biomarkers improves mortality prediction in acute lung injury</article-title>. <source>Crit Care Med</source> (<year>2011</year>) <volume>39</volume>(<issue>4</issue>):<fpage>711</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1097/CCM.0b013e318207ec3c</pub-id><pub-id pub-id-type="pmid">21283009</pub-id></mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flori</surname><given-names>HR</given-names></name><name><surname>Ware</surname><given-names>LB</given-names></name><name><surname>Glidden</surname><given-names>D</given-names></name><name><surname>Matthay</surname><given-names>MA</given-names></name></person-group>. <article-title>Early elevation of plasma soluble intercellular adhesion molecule-1 in pediatric acute lung injury identifies patients at increased risk of death and prolonged mechanical ventilation</article-title>. <source>Pediatr Crit Care Med</source> (<year>2003</year>) <volume>4</volume>(<issue>3</issue>):<fpage>315</fpage>–<lpage>21</lpage>.<pub-id pub-id-type="doi">10.1097/01.PCC.0000074583.27727.8E</pub-id><pub-id pub-id-type="pmid">12831413</pub-id></mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samransamruajkit</surname><given-names>R</given-names></name><name><surname>Prapphal</surname><given-names>N</given-names></name><name><surname>Deelodegenavong</surname><given-names>J</given-names></name><name><surname>Poovorawan</surname><given-names>Y</given-names></name></person-group>. <article-title>Plasma soluble intercellular adhesion molecule-1 (sICAM-1) in pediatric ARDS during high frequency oscillatory ventilation: a predictor of mortality</article-title>. <source>Asian Pac J Allergy Immunol</source> (<year>2005</year>) <volume>23</volume>(<issue>4</issue>):<fpage>181</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">16572737</pub-id></mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>AM</given-names></name><name><surname>Yan</surname><given-names>SD</given-names></name><name><surname>Yan</surname><given-names>SF</given-names></name><name><surname>Stern</surname><given-names>DM</given-names></name></person-group>
<article-title>The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses</article-title>. <source>J Clin Invest</source> (<year>2001</year>) <volume>108</volume>(<issue>7</issue>):<fpage>949</fpage>–<lpage>55</lpage>.<pub-id pub-id-type="doi">10.1172/JCI200114002</pub-id><pub-id pub-id-type="pmid">11581294</pub-id></mixed-citation></ref><ref id="B29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uchida</surname><given-names>T</given-names></name><name><surname>Shirasawa</surname><given-names>M</given-names></name><name><surname>Ware</surname><given-names>LB</given-names></name><name><surname>Kojima</surname><given-names>K</given-names></name><name><surname>Hata</surname><given-names>Y</given-names></name><name><surname>Makita</surname><given-names>K</given-names></name><etal></etal></person-group>
<article-title>Receptor for advanced glycation end-products is a marker of type I cell injury in acute lung injury</article-title>. <source>Am J Respir Crit Care Med</source> (<year>2006</year>) <volume>173</volume>(<issue>9</issue>):<fpage>1008</fpage>–<lpage>15</lpage>.<pub-id pub-id-type="doi">10.1164/rccm.200509-1477OC</pub-id><pub-id pub-id-type="pmid">16456142</pub-id></mixed-citation></ref><ref id="B30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Sato</surname><given-names>E</given-names></name><name><surname>Fujiwara</surname><given-names>N</given-names></name><name><surname>Kawagoe</surname><given-names>Y</given-names></name><name><surname>Maeda</surname><given-names>S</given-names></name><name><surname>Yamagishi</surname><given-names>S</given-names></name></person-group>
<article-title>Increased levels of soluble receptor for advanced glycation end products (sRAGE) and high mobility group box 1 (HMGB1) are associated with death in patients with acute respiratory distress syndrome</article-title>. <source>Clin Biochem</source> (<year>2011</year>) <volume>44</volume>(<issue>8–9</issue>):<fpage>601</fpage>–<lpage>4</lpage>.<pub-id pub-id-type="doi">10.1016/j.clinbiochem.2010.12.014</pub-id><pub-id pub-id-type="pmid">21211520</pub-id></mixed-citation></ref><ref id="B31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Narvaez-Rivera</surname><given-names>RM</given-names></name><name><surname>Rendon</surname><given-names>A</given-names></name><name><surname>Salinas-Carmona</surname><given-names>MC</given-names></name><name><surname>Rosas-Taraco</surname><given-names>AG</given-names></name></person-group>. <article-title>Soluble RAGE as a severity marker in community acquired pneumonia associated sepsis</article-title>. <source>BMC Infect Dis</source> (<year>2012</year>) <volume>12</volume>:<fpage>15</fpage>.<pub-id pub-id-type="doi">10.1186/1471-2334-12-15</pub-id><pub-id pub-id-type="pmid">22264245</pub-id></mixed-citation></ref><ref id="B32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Determann</surname><given-names>RM</given-names></name><name><surname>Millo</surname><given-names>JL</given-names></name><name><surname>Waddy</surname><given-names>S</given-names></name><name><surname>Lutter</surname><given-names>R</given-names></name><name><surname>Garrard</surname><given-names>CS</given-names></name><name><surname>Schultz</surname><given-names>MJ</given-names></name></person-group>. <article-title>Plasma CC16 levels are associated with development of ALI/ARDS in patients with ventilator-associated pneumonia: a retrospective observational study</article-title>. <source>BMC Pulm Med</source> (<year>2009</year>) <volume>9</volume>:<fpage>49</fpage>.<pub-id pub-id-type="doi">10.1186/1471-2466-9-49</pub-id><pub-id pub-id-type="pmid">19958527</pub-id></mixed-citation></ref><ref id="B33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Determann</surname><given-names>RM</given-names></name><name><surname>Royakkers</surname><given-names>AA</given-names></name><name><surname>Haitsma</surname><given-names>JJ</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Slutsky</surname><given-names>AS</given-names></name><name><surname>Ranieri</surname><given-names>VM</given-names></name><etal></etal></person-group>
<article-title>Plasma levels of surfactant protein D and KL-6 for evaluation of lung injury in critically ill mechanically ventilated patients</article-title>. <source>BMC Pulm Med</source> (<year>2010</year>) <volume>10</volume>:<fpage>6</fpage>.<pub-id pub-id-type="doi">10.1186/1471-2466-10-6</pub-id><pub-id pub-id-type="pmid">20158912</pub-id></mixed-citation></ref><ref id="B34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Salido</surname><given-names>A</given-names></name><name><surname>Onoro</surname><given-names>G</given-names></name><name><surname>Melen</surname><given-names>GJ</given-names></name><name><surname>Gomez-Pina</surname><given-names>V</given-names></name><name><surname>Serrano-Gonzalez</surname><given-names>A</given-names></name><name><surname>Ramirez-Orellana</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>Serum sRAGE as a potential biomarker for pediatric bronchiolitis: a pilot study</article-title>. <source>Lung</source> (<year>2015</year>) <volume>193</volume>(<issue>1</issue>):<fpage>19</fpage>–<lpage>23</lpage>.<pub-id pub-id-type="doi">10.1007/s00408-014-9663-9</pub-id><pub-id pub-id-type="pmid">25355250</pub-id></mixed-citation></ref><ref id="B35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ware</surname><given-names>LB</given-names></name><name><surname>Matthay</surname><given-names>MA</given-names></name><name><surname>Parsons</surname><given-names>PE</given-names></name><name><surname>Thompson</surname><given-names>BT</given-names></name><name><surname>Januzzi</surname><given-names>JL</given-names></name><name><surname>Eisner</surname><given-names>MD</given-names></name><etal></etal></person-group>
<article-title>Pathogenetic and prognostic significance of altered coagulation and fibrinolysis in acute lung injury/acute respiratory distress syndrome</article-title>. <source>Crit Care Med</source> (<year>2007</year>) <volume>35</volume>(<issue>8</issue>):<fpage>1821</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1097/01.CCM.0000221922.08878.49</pub-id><pub-id pub-id-type="pmid">17667242</pub-id></mixed-citation></ref><ref id="B36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bertozzi</surname><given-names>P</given-names></name><name><surname>Astedt</surname><given-names>B</given-names></name><name><surname>Zenzius</surname><given-names>L</given-names></name><name><surname>Lynch</surname><given-names>K</given-names></name><name><surname>LeMaire</surname><given-names>F</given-names></name><name><surname>Zapol</surname><given-names>W</given-names></name><etal></etal></person-group>
<article-title>Depressed bronchoalveolar urokinase activity in patients with adult respiratory distress syndrome</article-title>. <source>N Engl J Med</source> (<year>1990</year>) <volume>322</volume>(<issue>13</issue>):<fpage>890</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1056/NEJM199003293221304</pub-id><pub-id pub-id-type="pmid">2314423</pub-id></mixed-citation></ref><ref id="B37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agrawal</surname><given-names>A</given-names></name><name><surname>Zhuo</surname><given-names>H</given-names></name><name><surname>Brady</surname><given-names>S</given-names></name><name><surname>Levitt</surname><given-names>J</given-names></name><name><surname>Steingrub</surname><given-names>J</given-names></name><name><surname>Siegel</surname><given-names>MD</given-names></name><etal></etal></person-group>
<article-title>Pathogenetic and predictive value of biomarkers in patients with ALI and lower severity of illness: results from two clinical trials</article-title>. <source>Am J Physiol Lung Cell Mol Physiol</source> (<year>2012</year>) <volume>303</volume>(<issue>8</issue>):<fpage>L634</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1152/ajplung.00195.2012</pub-id><pub-id pub-id-type="pmid">22865551</pub-id></mixed-citation></ref><ref id="B38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sapru</surname><given-names>A</given-names></name><name><surname>Curley</surname><given-names>MA</given-names></name><name><surname>Brady</surname><given-names>S</given-names></name><name><surname>Matthay</surname><given-names>MA</given-names></name><name><surname>Flori</surname><given-names>H</given-names></name></person-group>. <article-title>Elevated PAI-1 is associated with poor clinical outcomes in pediatric patients with acute lung injury</article-title>. <source>Intensive Care Med</source> (<year>2010</year>) <volume>36</volume>(<issue>1</issue>):<fpage>157</fpage>–<lpage>63</lpage>.<pub-id pub-id-type="doi">10.1007/s00134-009-1690-2</pub-id><pub-id pub-id-type="pmid">19855955</pub-id></mixed-citation></ref><ref id="B39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seam</surname><given-names>N</given-names></name><name><surname>Meduri</surname><given-names>GU</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Nylen</surname><given-names>ES</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Schultz</surname><given-names>MJ</given-names></name><etal></etal></person-group>
<article-title>Effects of methylprednisolone infusion on markers of inflammation, coagulation, and angiogenesis in early acute respiratory distress syndrome</article-title>. <source>Crit Care Med</source> (<year>2012</year>) <volume>40</volume>(<issue>2</issue>):<fpage>495</fpage>–<lpage>501</lpage>.<pub-id pub-id-type="doi">10.1097/CCM.0b013e318232da5e</pub-id><pub-id pub-id-type="pmid">21983371</pub-id></mixed-citation></ref><ref id="B40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Shan</surname><given-names>Q</given-names></name><name><surname>Jiang</surname><given-names>L</given-names></name><name><surname>Zhu</surname><given-names>B</given-names></name><name><surname>Xi</surname><given-names>X</given-names></name></person-group>. <article-title>Quantitative proteomic analysis by iTRAQ for identification of candidate biomarkers in plasma from acute respiratory distress syndrome patients</article-title>. <source>Biochem Biophys Res Commun</source> (<year>2013</year>) <volume>441</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1016/j.bbrc.2013.09.027</pub-id><pub-id pub-id-type="pmid">24041686</pub-id></mixed-citation></ref><ref id="B41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gold</surname><given-names>L</given-names></name><name><surname>Walker</surname><given-names>JJ</given-names></name><name><surname>Wilcox</surname><given-names>SK</given-names></name><name><surname>Williams</surname><given-names>S</given-names></name></person-group>. <article-title>Advances in human proteomics at high scale with the SOMAscan proteomics platform</article-title>. <source>N Biotechnol</source> (<year>2012</year>) <volume>29</volume>(<issue>5</issue>):<fpage>543</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1016/j.nbt.2011.11.016</pub-id><pub-id pub-id-type="pmid">22155539</pub-id></mixed-citation></ref></ref-list></back></article>